DRUGS related term(s) Crime; Pharmaceuticals

Addresses

Election Night Speech: Phil Scott, Governor of Vermont, S7907 [19DE]

Amendments

Dept. of HHS: ensure doctors have access to patient treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (H.R. 6082), consideration (H. Res. 949), H5302 [20JN]

Dept. of Homeland Security: strengthen border security and increase resources for enforcement of immigration laws (H.R. 6136), H5447 [21JN]

Dept. of HUD: set aside section 8 housing vouchers for supportive and transitional housing for individuals recovering from opioid use disorders (H.R. 5735), H5179, H5180, H5181, H5182, H5183 [14JN]

——— set aside section 8 housing vouchers for supportive and transitional housing for individuals recovering from opioid use disorders (H.R. 5735), consideration (H. Res. 934), H5113 [13JN]

Diseases and disorders: authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur within months, or with another eligible illness (H.R. 5247), consideration (H. Res. 787), H1709 [20MR]

Drug abuse: provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), S6063 [6SE], S6193 [17SE], H5522, H5560, H5561, H5562, H5564, H5565, H5566 [22JN]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), consideration (H. Res. 949), H5302 [20JN]

FTC: prohibit marketing of bogus opioid treatment programs or products (S. 2842), S2776 [17MY]

Government regulations: clarify how synthetic drugs known as analogues are to be regulated (H.R. 2851), H5212, H5215, H5216, H5217, H5218 [15JN]

——— clarify how synthetic drugs known as analogues are to be regulated (H.R. 2851), consideration (H. Res. 934), H5113 [13JN]

——— prevent regulatory oversight from disrupting ability of emergency medical personnel to administer certain controlled substances (S. 916), S2881, S2882, S2884 [23MY]

Health: authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), consideration (H. Res. 905), H4300 [22MY]

Insurance: ensure that health insurance issuers and group health plans do not prohibit pharmacy providers from providing certain information to enrollees (S. 2554), S6062 [6SE], S6179 [17SE]

Medicaid: allow States to provide services for certain individuals with opioid use disorders in mental institutions (H.R. 5797), H5339, H5340, H5341 [20JN]

——— allow States to provide services for certain individuals with opioid use disorders in mental institutions (H.R. 5797), consideration (H. Res. 949), H5302 [20JN]

Medicare: prohibit health plans and pharmacy benefit managers from restricting pharmacies from informing individuals regarding prices for certain drugs and biologicals (S. 2553), S6030, S6033 [4SE]

National Criminal Justice Commission: establish (S. 573), S8030, S8037 [22DE]

Prematurity Research Expansion and Education for Mothers Who Deliver Infants Early (PREEMIE) Act: revise and extend (S. 3029), S6148, S6153, S6154 [12SE]

Taxation: include certain over-the-counter medical products as qualified medical expenses (H.R. 6199), consideration (H. Res. 1012), H7104 [24JY]

U.S. Customs and Border Protection: provide for processing of certain international mail shipments and advance electronic information on international mail shipments to target opioid shipments (H.R. 5788), consideration (H. Res. 934), H5113 [13JN]

Articles and editorials

4-Block Radius on the West Side Is at the Heart of Chicago’s Opioid Epidemic, H5169 [14JN]

Opioid Crisis Foretold, H5111 [13JN]

Pelosi Pulled Strings To Let Dying Dallas Lawyer Baron Try Experimental Cancer Drug, H1708 [20MR]

Secret Story of How America Lost the Drug War With the Taliban (excerpt), H6107 [11JY]

There’s Something Huge Missing From the White House’s Prison Bill, H4318 [22MY]

To Pay for Wall, Trump Would Cut Proven Border Security Measures, S83 [9JA]

U.S. Centers Force Migrant Children To Take Drugs—Lawsuit, H5441 [21JN]

U.S. Lawmakers Seek To Criminalize Doping in Global Competitions, H5187 [14JN], E830 [12JN]

Bills and resolutions

Advertising: require drug manufacturers to disclose prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug (see H.R. 6576), H7722 [26JY] (see H. Con. Res. 146), H10511 [20DE]

African Americans: increase upward social mobility of Black families and help ensure equal protection under the law (see H.R. 5785), H3935 [11MY]

Antitrust policy: enhance competition for prescription drugs by increasing ability of Dept. of Justice and FTC to enforce existing antitrust laws relative to biologic and biosimilar products (see H.R. 6478), H6649 [23JY]

Appalachian Regional Commission: allow funding to be used to address impacts of opioid addiction on workforce development and economic growth in Appalachia (see H.R. 5294), H1651 [15MR]

Aviation: prioritize and support Human Intervention Motivation Study (HIMS) program for flight crewmembers and Flight Attendant Drug and Alcohol Program (FADAP) for flight attendants (see S. 2935), S2877 [23MY]

Bureau of Prisons: improve treatment of Federal prisoners who are primary caretaker parents (see H.R. 5575), H3441 [18AP]

Business and industry: impose a fee on opioid manufacturers to fund an increase in drug addiction treatment capacity (see S. 3711), S7319 [5DE]

——— require retail sellers of opioids to verify identity of prospective purchaser and enter certain information about purchase into respective State’s prescription drug monitoring system (see H.R. 5219), H1501 [8MR]

CDC: carry out certain activities to prevent controlled substances overdoses (see H.R. 5812), H3976 [15MY]

——— provide for systematic data collection, analysis, and epidemiological research on neonatal abstinence syndrome (see S. 2658), S2120 [12AP]

——— reauthorize and expand a program of surveillance and education regarding infections associated with injection drug use (see S. 2579), S1845 [20MR] (see H.R. 5353), H1728 [20MR]

Centers for Medicare & Medicaid Services: compel manufacturers to correct inaccurate classification data reported to Medicaid rebate program (see H.R. 5712), H3833 [8MY]

——— provide for an action plan to prevent opioid addictions and enhance access to medication-assisted treatment (see S. 2769), S2484 [26AP] (see H.R. 5590), H3505 [24AP]

Central America: redirect foreign assistance provided to El Salvador, Guatemala, and Honduras and target it to fight systemic corruption and address driving causes of illegal immigration into the U.S. (see H. Res. 1092), H9151 [27SE]

Chemicals: include fentanyl analogues under schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (see H.R. 4922), H782 [5FE]

Children and youth: establish a grant program to address impact of substance use-related trauma on children and youth in public schools (see S. 2754), S2440 [25AP]

Colleges and universities: designate institutions of higher education that provide research, data, and leadership on continuous manufacturing as National Centers of Excellence in Continuous Pharmaceutical Manufacturing (see H.R. 5568), H3441 [18AP]

Commission To Study and Establish a Fair and Humane System of Immigration and Customs Enforcement: establish (see H.R. 6361), H6173 [12JY]

Committee on Homeland Security and Governmental Affairs (Senate): authorize release of Permanent Subcommittee on Investigations records on investigation into purchase and shipment of illicit opioids (see S. Res. 379), S468 [23JA]

Comprehensive Addiction and Recovery Act: reauthorize and expand (see S. 2456), S1243 [27FE] (see H.R. 5311), H1651 [15MR]

Courts: provide certain protections from civil liability for individuals prescribing or administering opioid overdose drugs (see S. 2981), S2924 [24MY] (see H.R. 4955), H902 [6FE]

Crime: clarify that using drugs to cause a person to engage in a commercial sex act constitutes coercion and using drugs to provide or obtain the labor or services of a person constitutes forced labor (see S. 2429), S967 [14FE] (see H.R. 5027), H1178 [14FE]

——— establish criminal penalties for unlawful payments for referrals to recovery homes, clinical treatment facilities, and laboratories (see H.R. 6878), H8884 [25SE]

——— establish criminal penalties for unlawful payments for referrals to recovery homes and clinical treatment facilities (see S. 3254), S5108 [19JY] (see H.R. 6902), H9089 [26SE]

——— prohibit awarding credit toward service of sentences for satisfactory behavior for certain drug offenses (see S. 3477), S6223 [18SE] (see H.R. 6844), H8737 [20SE]

DEA: allow for prescription of medication-assisted treatment and other controlled substances via telemedicine to improve access to opioid addiction treatment (see H.R. 5483), H3209 [12AP]

——— allow home hospice providers to dispose of leftover prescription medications on behalf of their patients and establish written policies and documentation on such disposals (see S. 2659, 2661), S2120 [12AP]

——— amend certain regulations so that practitioners may not administer more than 3 days’ medication to a person at one time when administering narcotics in order to relieve acute withdrawal symptoms (see H.R. 5770), H3929 [10MY]

——— clarify process for denying, revoking, or suspending a registration to manufacture, distribute, or dispense a controlled substance (see H.R. 5267), H1542 [13MR]

——— commemorate anniversary, honor employees killed or injured in service, and thank all past and present employees (see S. Res. 578), S5066 [18JY]

——— deem drugs or other substances that act as opioid mu receptor antagonists to be in Schedule I of the Controlled Substances Act, designating they have high potential for abuse and have no medical use (see H.R. 5298), H1651 [15MR]

——— enhance opioid quota-setting authority by improving transparency and allowing adjustment of opioid production quotas to prevent diversion and abuse (see S. 2535), S1629 [12MR]

——— establish a national clearinghouse for all orders of controlled substances and require such orders pass through a database to identify suspicious orders and notify suppliers before orders are filled (see S. 3282), S5423 [26JY] (see H.R. 6600), H7723 [26JY]

——— improve systems for identifying diversion of controlled substances (see S. 2837), S2643 [14MY]

——— make publicly available online a report on the sale of controlled substances and controlled substance analogues over the Internet (see H.R. 5021), H1177 [14FE]

——— provide grants to certain States to increase participation in drug take-back programs (see S. 2645), S2075 [11AP] (see H.R. 5628), H3705 [26AP]

——— regulate selective androgen receptor modulators in the same manner as anabolic steroids (see S. 2742), S2391 [24AP]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders (see S. 2838), S2678 [15MY] (see H.R. 6491), H7154 [24JY] (see H.R. 6779), H8169 [12SE]

——— restore ability to target pharmaceutical companies distributing opioids in certain communities by implementing a probable cause standard for intervention and striking the corrective action plan option (see S. 2493), S1338 [5MR] (see H.R. 6702), H7870 [5SE]

——— suspend a controlled substances registration if there is a likelihood of a threat of diversion of a controlled substance (see S. 2561), S1765 [15MR]

Dept. of Agriculture: establish a Rural Health Liaison (see S. 2894), S2835 [22MY] (see H.R. 4945), H901 [6FE]

——— establish Animal Disease and Disaster Prevention, Surveillance, and Rapid Response Program and National Livestock Vaccine Bank (see S. 3681), S7241 [29NO]

——— provide for State and tribal regulation of hemp production (see S. 2667), S2120 [12AP] (see H.R. 5485), H3209 [12AP]

Dept. of Defense: authorize use of certain funds for combating opioid trafficking and abuse (see H.R. 5546), H3440 [18AP]

——— develop a strategy to recruit and retain mental health providers and direct military departments to develop medication monitoring programs (see H.R. 6712), H7870 [5SE]

——— establish a prescription drug monitoring program for Armed Forces members (see H.R. 5591), H3505 [24AP]

——— prevent overprescription of opioids to TRICARE recipients by limiting duration of initial prescriptions (see H.R. 6165), H5362 [20JN]

Dept. of Education: establish State-Federal partnerships to provide students with debt-free college, provide Pell Grant eligibility to certain immigrants, and restore assistance eligibility for drug-related offenses (see S. 2598), S1947 [22MR] (see H.R. 5384), H2040 [22MR]

——— provide grants to communities affected by substance use disorder to enable those communities to plan for and implement full-service community schools (see S. 3362), S5831 [22AU]

——— require institutions of higher education to offer substance use disorder prevention, treatment, and recovery services to students (see H.R. 6535), H7686 [25JY]

Dept. of HHS: address use of opioids and substance use disorders relative to pregnant women and babies (see H.R. 5492), H3209 [12AP]

——— allow delivery of medical supplies by unmanned aerial systems (see H.R. 7395), H10586 [21DE]

——— authorize a loan repayment program for substance use disorder treatment employees (see S. 2524), S1578 [8MR] (see H.R. 5102), H1332 [27FE]

——— authorize certain substance abuse recovery services grants to be used to establish regional technical assistance centers (see H.R. 5587), H3452 [23AP]

——— authorize grants to health centers to expand access to evidence-based substance abuse treatment services (see H.R. 5456), H3095 [10AP]

——— authorize Substance Abuse and Mental Health Services Administration development of best practices for recovery residences that promote sustained recovery from substance use disorders (see S. 2678), S2141 [16AP]

——— award grants to train health care professionals to treat opioid addiction and other substance use disorders using technology-enabled models (see S. 2606), S1947 [22MR]

——— clarify intent, enhance integrity, and protect and expand 340B discount drug program to meet the needs of the opioid drug crisis (see H.R. 6071), H5093 [12JN]

——— clarify requirements for receiving certain grants through the National Mental Health and Substance Use Policy Laboratory (see S. 2626), S1948 [22MR]

——— conduct a demonstration program to test alternative pain management protocols to limit use of opioids in emergency departments (see S. 2516), S1452 [7MR] (see H.R. 5197), H1476 [7MR] (see H.R. 5558), H3441 [18AP]

——— conduct a family recovery and reunification program to help reunify families and protect children with parents or guardians with a substance use disorder who have temporarily lost custody of their children (see S. 2926), S2836 [22MY]

——— conduct a study and submit a report on barriers to accessing abuse-deterrent opioid formulations for certain Medicare enrollees (see H.R. 5582), H3451 [23AP]

——— conduct programs to address usage of illicit drugs, particularly fentanyl (see S. 3500), S6304 [25SE] (see H.R. 5580), H3451 [23AP]

——— consider Margaret R. Pardee Memorial Hospital in Hendersonville, NC, as a covered entity for purposes of the 340B drug discount program (see H.R. 7266), H10168 [12DE]

——— consider State analysis and sharing of prescription drug monitoring program data in determining prescription drug monitoring program grants to States (see S. 2451), S1219 [26FE]

——— develop a joint action plan to reduce single use drug waste and better manage costs relative to drug vial sizes and drug delivery systems (see H.R. 5867), H4209 [17MY] (see H.R. 6142), H5284 [19JN]

——— develop guidance on pain management and prevention of opioid use disorder for hospitals receiving payments under Medicare (see H.R. 5699), H3833 [8MY] (see H.R. 5774), H3934 [11MY]

——— develop national milestones to measure success in curtailing the opioid epidemic (see S. 2931), S2877 [23MY]

——— develop strategy to implement recommendations to prevent and treat prenatal opioid abuse and neonatal abstinence syndrome (see H.R. 5562), H3441 [18AP] (see H.R. 5702), H3833 [8MY]

——— disseminate resources to early childhood care and education providers working with young children on ways to recognize and respond to children who may be impacted by trauma related to substance abuse (see H.R. 5889), H4284 [21MY]

——— encourage use of family-focused residential treatment programs (see S. 2924), S2835 [22MY]

——— enhance efforts to address antibiotic resistance (see S. 2469), S1286 [28FE]

——— ensure doctors have access to patient treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (see H.R. 6082), H5151 [13JN]

——— ensure doctors have access to patient treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (H.R. 6082), consideration (see H. Res. 949), H5283 [19JN]

——— ensure doctors have access to patients’ treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (see H.R. 5795), H3975 [15MY]

——— ensure medications are affordable through increasing transparency, spurring innovation, and protecting competition (see S. 3411), S6038 [5SE]

——— ensure that federally-funded programs and activities to prevent or treat mental health or substance use disorders are evidence-based (see H.R. 5272), H1607 [14MR]

——— enter into arrangement with National Academy of Sciences to conduct and update biennially study on effects of State legalized marijuana programs (see H.R. 6495), H7154 [24JY]

——— establish a grant program to create comprehensive opioid recovery centers (see S. 2589), S1947 [22MR] (see H.R. 5327), H1697 [19MR]

——— establish a moratorium on new enrollment of disproportionate share hospitals into the 340B discount drug program and require basic data reporting (see S. 2312), S187 [16JA]

——— establish a pilot program to help individuals in recovery from a substance use disorder transition from treatment to independent living and the workforce (see S. 2730), S2342 [23AP] (see H.R. 5736), H3885 [9MY]

——— establish a technical expert panel for purposes of evaluating use of opioid-related quality measures under Medicare (see H.R. 5779), H3935 [11MY]

——— establish and operate recovery home certification programs (see H.R. 5100), H1332 [27FE]

——— establish community action opioid response grant program (see S. 2636), S2040 [10AP] (see H.R. 5124), H1333 [27FE]

——— establish grant program within the Substance Abuse and Mental Health Services Administration to create peer support recovery networks (see S. 2657), S2120 [12AP]

——— establish Office of Drug Manufacturing to manufacture certain generic drugs in order to reduce prices, increase competition, and address shortages in the prescription drug market (see S. 3775), S7790 [18DE] (see H.R. 7348), H10336 [19DE]

——— establish Prescription Safety Alert System to combat prescription drug abuse by collecting, maintaining, and providing to dispensers patients’ prescription and dispensing history (see H.R. 6688), H7776 [28AU]

——— establish reference prices for prescription drugs and require drug companies to offer drugs at such prices as condition of participation in Federal health programs (see S. 3680), S7241 [29NO]

——— extend floor on area wage index under inpatient prospective payment system and provide eligibility for discounted drug prices under 340B drug pricing program to certain sole community hospitals (see H.R. 5498), H3209 [12AP]

——— improve treatment and early interventions for pregnant and postpartum women and infants affected by substance use disorder (see S. 2710), S2321 [19AP]

——— include additional covered recipients for transparency reports required of manufacturers of opioids (see S. 3565), S6770 [10OC]

——— increase awareness of treatment referral routing service of the Substance Abuse and Mental Health Services Administration (see H.R. 4769), H168 [11JA]

——— issue guidance relative to expedited approval of certain drugs (see H.R. 5806), H3976 [15MY]

——— issue guidelines for prescribing naloxone (see H.R. 5926), H4692 [23MY]

——— make available on Centers for Medicare & Medicaid Services website opioid prescribing guidance for certain Medicare beneficiaries and update such guidance periodically (see H.R. 5777), H3934 [11MY]

——— make Indian tribes eligible for State Targeted Response to the Opioid Crisis Grants and expand use to include methamphetamine abuse (see H.R. 5140), H1340 [1MR]

——— notify health care providers about permitted disclosures under privacy laws of health information during emergencies, including overdoses (see H.R. 5695), H3782 [7MY]

——— nullify certain contractual provisions prohibiting or penalizing a pharmacist’s disclosure of availability of equivalent alternative drugs or methods of purchasing less expensive drugs (see H.R. 5343), H1727 [20MR]

——— permit certain disclosures of health information during emergencies, including overdoses (see S. 2676), S2141 [16AP]

——— prohibit price gouging in the sale of drugs by requiring pharmaceutical companies to provide justification for price increases and penalize such companies if increases are deemed unreasonable (see S. 3754), S7586 [13DE]

——— provide assistance to States in complying with and implementing child abuse and neglect prevention and treatment programs to promote better protections for young children and family-centered responses (see H.R. 5890), H4284 [21MY]

——— provide coordinated care to patients who have experienced a non-fatal overdose after emergency room discharge (see S. 2610), S1947 [22MR] (see H.R. 5176), H1441 [6MR]

——— provide for certain user fees under the 340B drug discount program (see H.R. 6240), H5815 [27JN]

——— provide for opioid quality measures development and a technical expert panel on reducing surgical setting opioid use and data collection on perioperative opioid use (see H.R. 5774), H3934 [11MY]

——— provide for prevention and treatment of substance abuse grants to recovery community organizations (see H.R. 5408), H3046 [23MR]

——— provide for public disclosure of charges for certain hospital and ambulatory surgical center treatment episodes (see H.R. 6508), H7685 [25JY]

——— provide for regional centers of excellence in substance use disorder education (see H.R. 5261), H1542 [13MR]

——— provide for sharing of health information concerning an individual’s substance abuse history and treatment by certain entities (see H.R. 5009), H1126 [13FE]

——— provide grants for eligible entities to provide technical assistance to outlier prescribers of opioids (see H.R. 5796), H3975 [15MY]

——— provide grants for treatment of heroin, cocaine, methamphetamine, ecstasy, and PCP abuse (see H.R. 4899), H731 [30JA]

——— provide grants to State alcohol and drug agencies to use recovery coaches in hospital emergency rooms (see S. 2609), S1947 [22MR]

——— provide grants to States to improve and coordinate their response to ensure safety, permanency, and well-being of children at high risk for abuse and neglect due to substance abuse (see S. 2696), S2261 [18AP]

——— provide guidance to States regarding Federal reimbursement for services and treatment for substance use disorders under Medicaid using telehealth services (see S. 2904), S2835 [22MY] (see H.R. 6778), H8169 [12SE]

——— provide guidance to States relative to Medicaid items and services for non-opioid pain treatment and management (see S. 2911), S2835 [22MY]

——— provide research on, and recommendations for, opioid prescribing practices for pregnant women (see H.R. 5646), H3741 [27AP]

——— provide the Dept. of Justice certain notifications of improper prescribing of controlled substances under the Medicare program (see H.R. 7369), H10510 [20DE]

——— publish data relative to prevalence of substance use disorders in the Medicaid beneficiary population and treatment of substance use disorders under Medicaid (see S. 2912), S2835 [22MY]

——— reauthorize, improve, and make Indian tribes eligible for State Targeted Response to the Opioid Crisis Grants (see S. 2437), S1164 [15FE]

——— report on extent to which certain Medicare Advantage plans include supplemental health care benefits designed to treat or prevent substance use disorders (see H.R. 5725), H3884 [9MY]

——— require certain disproportionate share hospital (DSH) covered entities under the 340B drug discount program to submit reports on low-income utilization rates of outpatient hospital services furnished by such entities (see H.R. 5598), H3505 [24AP]

——— require prescribers to complete continuing medical education courses on potential dangers and risks of prescribing opioids (see H.R. 5581), H3451 [23AP]

——— require States to operate drug management programs for at-risk beneficiaries (see H.R. 5808), H3976 [15MY]

——— study and submit to Congress a report recommending how to improve use of non-opioid treatments for acute and chronic pain management for individuals under Medicare (see S. 3008), S3035 [6JN] (see H.R. 5722), H3884 [9MY]

——— support development of evidence-based family-focused residential treatment programs (see S. 2923), S2835 [22MY]

——— support endemic orphan fungal disease research, incentivize valley fever vaccine development, and discover new antifungal therapies and diagnostics (see H.R. 6562), H7721 [26JY]

——— update or issue one or more guidances addressing alternative methods for data collection on opioid sparing and inclusion of such data in product labeling (see H.R. 5473), H3146 [11AP]

Dept. of Homeland Security: establish a narcotic drug screening technology pilot program to combat illicit opioid importation (see S. 3047), S3601 [11JN]

——— establish Border Tunnel Task Forces (see H.R. 6740), H7941 [7SE]

——— establish joint task force to integrate border security operations to detect, interdict, disrupt, and prevent narcotics such as fentanyl and other synthetic opioids from entering U.S. (see S. 2864), S2724 [16MY] (see H.R. 5762), H3929 [10MY]

——— increase number of U.S. Customs and Border Protection officers and staff and require reports that identify staffing, infrastructure, and equipment needed to enhance security at ports of entry (see S. 2314), S253 [17JA] (see H.R. 4940), H901 [6FE]

——— maintain situational awareness and operational control of high traffic areas along the borders through immigration enforcement and enhanced illicit drug importation technology (see S. 3478), S6223 [18SE]

——— strengthen border security and increase resources for enforcement of immigration laws (see H.R. 6136), H5284 [19JN]

——— strengthen border security and increase resources for enforcement of immigration laws (H.R. 6136), consideration (see H. Res. 953), H5361 [20JN]

——— support officers and employees of U.S. Immigration and Customs Enforcement and denounce efforts to abolish agency (see S. Res. 572), S4916 [11JY] (see H. Res. 990), H6111 [11JY]

——— support officers and employees of U.S. Immigration and Customs Enforcement, condemn harassment and threats against such individuals, and call for resignation of Portland, OR, Mayor, Ted Wheeler (see S. Res. 611), S5759 [21AU] (see H. Res. 1048), H7781 [31AU]

——— terminate U.S. Immigration and Customs Enforcement (see H.R. 6361), H6173 [12JY]

Dept. of HUD: clarify applicability of the Fair Housing Act to recovery facilities to allow local communities to prevent location of sober living homes in residential neighborhoods (see H.R. 5724), H3884 [9MY]

——— set aside section 8 housing vouchers for supportive and transitional housing for individuals recovering from opioid use disorders (see H.R. 5735), H3885 [9MY]

——— set aside section 8 housing vouchers for supportive and transitional housing for individuals recovering from opioid use disorders (H.R. 5735), consideration (see H. Res. 934), H5092 [12JN]

Dept. of Justice: make grants to, and enter into agreements with, State and local governments for programs to provide medication-assisted treatment to individuals incarcerated in the jurisdiction who are addicted to opioids (see H.R. 7079), H9438 [19OC]

——— prohibit Federal prosecution of individuals using medical or recreational marijuana in States with legalized marijuana (see H.R. 5050), H1212 [15FE]

——— prohibit use of amounts from Asset Forfeiture Fund for DEA Domestic Cannabis Suppression/Eradication Program (see H.R. 4816), H477 [17JA]

——— protect State and local witnesses from intimidation, authorize grants to purchase drug exposure personal protective equipment for first responders, and address organized crime and gang violence (see S. 3490), S6304 [25SE]

——— provide for programs to help reduce the risk that prisoners will recidivate upon release from prison (see S. 2795), S2517 [7MY] (see H.R. 5682), H3781 [7MY]

——— provide grants for drug disposal sites (see H.R. 5557), H3441 [18AP]

——— provide grants to State and local law enforcement agencies to purchase chemical screening devices to detect dangerous drugs and train personnel on use of such devices (see S. 2763), S2484 [26AP] (see H.R. 5871), H4209 [17MY]

——— reauthorize Comprehensive Opioid Abuse Grant Program (see H.R. 6029), H4979 [7JN]

——— require registration of tableting or encapsulating machines to assist law enforcement in identifying counterfeit pill makers (see S. 3281), S5423 [26JY] (see H.R. 6554), H7721 [26JY]

Dept. of Labor: establish an Advisory Committee on Opioids and the Workplace (see H.R. 5892), H4284 [21MY]

——— establish Jobs Plus Recovery programs to give individuals impacted by opioid addiction or substance use disorders access to job training and support services (see S. 2642), S2040 [10AP] (see H.R. 5679), H3781 [7MY]

Dept. of Transportation: improve controlled substances and alcohol testing (see S. 2848), S2679 [15MY]

——— modify requirements relative to reservation of highway funds for failure to enact or enforce open container laws and repeat intoxicated driver laws (see S. 3252), S5108 [19JY]

Dept. of Veterans Affairs: allow veterans to use, possess, or transport medical marijuana and to discuss the use of medical marijuana with departmental physicians as authorized by State law (see S. 3409), S6038 [5SE]

——— conduct and support research on the efficacy and safety of medicinal marijuana (see S. 2796), S2517 [7MY] (see H.R. 5520), H3342 [16AP]

——— ensure that certain medical centers have physical locations for disposal of controlled substances medications (see H.R. 6848), H8737 [20SE]

——— enter into an agreement with a federally funded research and development center to conduct surveys to measure cannabis use by veterans (see H.R. 7128), H9525 [14NO]

——— improve Medical Surgical Prime Vendor program by using multiple regional prime vendors and medical professionals with relevant expertise to develop the medical-surgical formulary (see S. 3737), S7431 [11DE] (see H.R. 5418), H3052 [29MR]

——— provide for a policy on medicinal cannabis (see H.R. 7130), H9525 [14NO]

——— provide training in use of medical cannabis for all departmental primary care providers (see H.R. 7129), H9525 [14NO]

——— report on opioid prescribing rates of physicians of the Veterans Health Administration and conduct pain management training for physicians with highest rates of opioid prescribing (see S. 2819), S2623 [10MY] (see H.R. 5829), H3977 [15MY]

Depts. of Education and HHS: provide substance use prevention and treatment grants for institutions of higher education (see S. 2791), S2517 [7MY]

Depts. of Labor and HHS: establish a pilot program to award competitive grants to counties and tribal entities to administer combined workforce training and drug addiction treatment and recovery programs (see S. 2646), S2075 [11AP]

Diseases and disorders: authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur within a matter of months, or with another eligible illness (see H.R. 5247), H1541 [13MR]

——— authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur within months, or with another eligible illness (H.R. 5247), consideration (see H. Res. 787), H1697 [19MR]

——— facilitate effective research on, and treatment of, neglected tropical diseases through coordinated domestic and international efforts (see S. 3212), S4951 [12JY]

——— recognize value of pre-exposure prophylaxis medication as an effective prevention tool in combating HIV, support research and usage of such medication, and ensure effective HIV prevention outreach (see H. Res. 960), H5648 [25JN]

Drug abuse: address the opioid crisis (see S. 2680), S2141 [16AP]

——— combat heroin epidemic and assist forensic labs with addressing seized drug identification backlogs (see H.R. 6074), H5093 [12JN]

——— develop and disseminate best practice guidelines for using data collected by prescription drug monitoring programs to identify drug diversion and abuse (see H.R. 6608), H7723 [26JY]

——— ensure equitable distribution of resources to address opioid drug abuse epidemic (see H.R. 5109), H1333 [27FE]

——— establish an interagency task force to improve Federal response to families impacted by substance abuse disorders (see H.R. 5891), H4284 [21MY]

——— improve oversight of new opioids and education of prescribers, limit availability of addictive painkillers, strengthen prescription drug monitoring, and establish drug disposal programs (see S. 2729), S2342 [23AP] (see H.R. 5865), H4209 [17MY]

——— making appropriations to address heroin and opioid drug abuse epidemic (see H.R. 4938), H901 [6FE]

——— prevent substance abuse and reduce demand for illicit narcotics (see S. 2789), S2485 [26AP] (see H.R. 5933), H4692 [23MY]

——— provide assistance to States and localities affected by the opioid epidemic and improve delivery of essential services to individuals with substance use disorders and their families (see S. 2700), S2261 [18AP] (see H.R. 5545), H3440 [18AP]

——— provide for a comprehensive, multifaceted approach to preventing and treating opioid addiction (see H.R. 5531), H3395 [17AP]

——— provide for additional flexibility relative to medication-assisted treatment for opioid use disorders (see S. 2317), S253 [17JA]

——— provide for opioid use disorder prevention, recovery, and treatment (see H.R. 6), H5151 [13JN]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), concur in Senate amendment (see H. Res. 1099), H9406 [28SE]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), consideration (see H. Res. 949), H5283 [19JN]

——— require awareness campaign regarding risk of abuse of prescription opioids if such drugs are not taken as prescribed to include information about dispensing options (see S. 2697), S2261 [18AP]

——— strengthen penalties on drug companies that fail to monitor and report suspicious opioid distribution practices and increase transparency of Federal oversight of opioid manufacturing and advertising (see S. 2440), S1164 [15FE]

EPA: exempt from certain Clean Air Act requirements law enforcement agency incinerator units when used for the sole purpose of destroying contraband or household pharmaceuticals (see H.R. 6291), H5974 [28JN]

——— study the presence of pharmaceuticals and personal care products in sources of drinking water (see H.R. 5548), H3440 [18AP]

FDA: allow for detention, refusal, and destruction of certain drugs offered for importation (see H.R. 5752), H3928 [10MY]

——— amend policies relative to postapproval study requirements for certain controlled substances (see H.R. 5811), H3976 [15MY]

——— clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (see S. 2315), S253 [17JA] (see H.R. 5333), H1698 [19MR] (see H.R. 7328), H10335 [19DE]

——— consider potential for misuse and abuse when determining whether to approve certain drugs (see H.R. 5803), H3976 [15MY]

——— deter opioid abuse and addiction through development of high-quality, evidence-based opioid analgesic prescribing guidelines (see H.R. 6133), H5283 [19JN]

——— encourage development of priority antimicrobial products through award of a transferable exclusivity extension period (see H.R. 6294), H5975 [28JN]

——— ensure valid generic drugs may enter the market by removing generic drug exclusivity period from any generic company that enters into pay-for-delay settlements with brand-name drug manufacturers (see S. 2476), S1286 [28FE]

——— establish Prescription Drug and Medical Device Price Review Board (see H.R. 5739), H3885 [9MY]

——— expand conditional approval pathway for more animal drugs (see H.R. 5599), H3505 [24AP]

——— hold pharmaceutical companies accountable for illegal marketing and distribution of opioid products and for their role in creating and exacerbating the opioid epidemic (see S. 2691), S2218 [17AP] (see H.R. 5782), H3935 [11MY]

——— increase authority to restrict entrance of illicit drugs into the U.S. through international mail facilities (see S. 2739), S2391 [24AP]

——— modify outdated drug labels to reflect new evidence relevant to the drug and its use (see S. 3519), S6355 [27SE]

——— prevent inter partes review process for challenging patents from diminishing competition in the pharmaceutical industry and provide incentives for drug innovation (see S. 3738), S7431 [11DE] (see H.R. 7251), H10102 [11DE]

——— provide for accelerated approval of non-opioid or non-addictive pain medications and treatments for substance use disorders (see S. 2669), S2141 [16AP]

——— provide greater oversight over advertising and other promotion materials for opioid drugs to ensure that such materials do not mislead consumers and exacerbate existing crisis (see S. 3420), S6059 [6SE]

——— reauthorize user fee programs relative to new animal drugs and generic new animal drugs (see S. 2434), S1164 [15FE] (see H.R. 5554), H3441 [18AP]

——— require guidance on consideration of claims of opioid sparing and on conditions under which to consider misuse and abuse of drugs in making certain determinations for safety (see S. 2665), S2120 [12AP]

——— require label of drugs with an increased risk of suicide or depression to prominently detail those side effects (see H.R. 6717), H7919 [6SE]

——— require manufacturers of drugs to post names of countries in which their drugs are manufactured on their Internet websites (see S. 3105), S4343 [21JN]

——— require review of durations of use of approved indications of medically-important antibiotics labeled for use in animals (see S. 3099), S4281 [20JN]

——— require risk evaluation and mitigation strategy communication plans provide information on State and Federal regulation of controlled substances including the option to partially fill a prescription (see S. 2608), S1947 [22MR]

——— require warning labels to be affixed to prescription opioid containers or packaging stating such drugs can cause dependence, addiction, and overdose (see S. 3428), S6142 [12SE]

——— shorten exclusivity period for brand name biological products (see H.R. 6577), H7722 [26JY]

——— strengthen authorities to address counterfeit drugs, illegal and synthetic opioids, and opioid-like substances (see H.R. 5228), H1501 [8MR]

Federal aid programs: allow for more flexibility relative to medication-assisted treatment for opioid use disorders and protect confidentiality of substance use disorder patient records (see H.R. 5807), H3976 [15MY]

——— recognize essential benefit of Medicare and Social Security programs to current enrollees and strengthen such programs for future generations (see H. Res. 1026), H7687 [25JY]

Federal employees: remove limitations on Federal employment for individuals legally using marijuana according to laws of the State in which they reside (see H.R. 6589), H7722 [26JY]

Foreign aid: withhold assistance from countries that do not monitor or prosecute production or distribution of illicit fentanyl and other synthetic drugs or do not require registration of tableting and encapsulating machines (see S. 3463), S6223 [18SE]

FTC: issue rules to promote competition and help consumers save money by giving them the freedom to choose where they buy prescription pet medications (see S. 2651), S2075 [11AP] (see H.R. 5472), H3146 [11AP]

——— prohibit marketing of bogus opioid treatment programs or products (see S. 2842), S2678 [15MY]

GAO: conduct a study and submit a report to Congress on best practices in use by Federal agencies and departments to reduce opioid usage following medical procedures (see H.R. 4903), H732 [30JA]

——— conduct study on how virtual currencies and online marketplaces are used to facilitate sex and drug trafficking (see S. 3179), S4734 [28JN] (see H.R. 6069), H5093 [12JN]

——— evaluate and report on inpatient and outpatient treatment capacity, availability, and needs (see S. 3048), S3601 [11JN]

——— study and report on State Medicaid agencies’ options relative to distribution of substance use disorder treatment medications (see S. 2909), S2835 [22MY]

——— study feasibility of establishing and maintaining automated system that tracks prescription drug prices (see H.R. 6593), H7722 [26JY]

——— submit a report on provision of peer support services under Medicaid (see S. 2892), S2834 [22MY]

Government regulations: clarify how synthetic drugs known as analogues are to be regulated (H.R. 2851), consideration (see H. Res. 934), H5092 [12JN]

——— study and report on policy and regulatory changes that may have contributed to the opioid epidemic (see H.R. 5914), H4583 [22MY]

Health: authorize, develop, and implement a coordinated tracking system of federally-funded initiatives and grant programs for substance abuse treatment, prevention, and enforcement (see H.R. 5980), H4732 [25MY]

——— authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), consideration (see H. Res. 905), H4283 [21MY]

——— provide for a technical expert panel to provide recommendations on reducing opioid use in the surgical setting and on best practices for pain management (see H.R. 5718), H3884 [9MY]

Health care facilities: authorize hospitals to dispose of controlled substances on behalf of patients who die at the hospital (see H.R. 6205), H5580 [22JN]

——— develop and identify indicators of potentially fraudulent and disreputable recovery housing operators (see S. 2828), S2623 [10MY] (see H.R. 6092), H5152 [13JN]

Health care professionals: authorize employees of a hospice program to handle controlled substances in the residence of a deceased hospice patient to assist in disposal (see H.R. 5041), H1211 [15FE]

——— improve and expand training for future and current physicians and mid-level health care providers on treating pain and prescribing opioids (see H. Con. Res. 136), H8726 [13SE]

——— improve medical student training on addiction treatment and facilitate certain registration waivers for physicians dispensing narcotic drugs for maintenance treatment or detoxification treatment (see S. 2711), S2321 [19AP]

——— provide for delivery of a controlled substance by a pharmacy to an administering practitioner (see H.R. 5202), H1476 [7MR]

Hezbollah (terrorist organization): determine designation as a significant foreign narcotics trafficker or a transnational criminal organization (see H.R. 5035), H1211 [15FE]

Housing: provide that an individual who uses marijuana in compliance with State law may not be denied occupancy of federally assisted housing (see H.R. 6152), H5285 [19JN]

Immigration: clarify admissibility and deportability of aliens acting in accordance with State and foreign marijuana laws (see H.R. 7275), H10169 [12DE]

——— fund construction of southern border wall, ensure compliance with Federal immigration law, and combat sanctuary cities, transnational gangs, human trafficking, and drugs (see H.R. 7059), H9430 [12OC]

——— strengthen border security by authorizing construction of a wall, improving technology, securing ports of entry, hiring more agents, using National Guard support, and penalizing illegal immigration (see H.R. 6415), H6557 [18JY]

——— use of budget reconciliation to establish a Border Wall and Security Trust Fund (see H.R. 7073), H9438 [19OC]

Insurance: cap prescription drug cost-sharing (see S. 3194), S4916 [11JY] (see H.R. 6340), H6111 [11JY]

——— ensure that health insurance issuers and group health plans do not prohibit pharmacy providers from providing certain information to enrollees (see S. 2554), S1735 [14MR] (see H.R. 6143), H5284 [19JN]

——— prohibit health insurance issuers, group health plans, Medicare Advantage organizations, and prescription drug plan sponsors from limiting drug price information a pharmacy may give to a consumer (see H.R. 6641), H7734 [31JY] (see H.R. 6733), H7941 [7SE]

——— require health insurance providers to cover oral cancer drugs on terms no less favorable than for cancer medications administered by a health care provider (see S. 3742), S7509 [12DE]

Law enforcement: allow use of counter drone technology to detect, monitor, and engage with unauthorized drones that pose a reasonable threat to the safety and security of certain facilities and assets (see H.R. 5366), H1754 [21MR]

——— improve prosecution of the sale and distribution of synthetic drugs known as analogues (see H.R. 6047), H4980 [7JN]

——— increase penalties for fentanyl trafficking (see S. 2481), S1316 [1MR] (see H.R. 6057), H5020 [8JN]

——— modify offenses relative to fentanyl (see S. 2635), S2012 [9AP] (see H.R. 5459), H3095 [10AP]

——— stop production of fentanyl and its trafficking into the U.S. from China (see H.R. 7091), H9448 [26OC]

Marijuana: allow States, territories, and Indian tribes to control regulation, remove industrial hemp from list of controlled substances, and maintain application of certain criminal offenses (see S. 3032), S3293 [7JN] (see H.R. 6043), H4979 [7JN]

——— decriminalize, use tax revenues to assist certain small businesses, research effects on driving and health, restrict advertising to protect children, and expunge certain marijuana-related convictions (see S. 3174), S4734 [28JN]

——— improve medical research (see H.R. 4825), H552 [18JA]

——— increase number of cannabis manufacturers registered under Controlled Substances Act for legitimate research purposes and allow VA health care providers to recommend federally-approved cannabis clinical trials (see H.R. 5634), H3705 [26AP]

——— make marijuana legal at the Federal level, incentivize States to change marijuana laws that disproportionately impact minority communities, and allow retroactive review of marijuana sentences (see H.R. 4815), H477 [17JA]

——— urge action to increase equity within the legal cannabis marketplace (see H. Res. 943), H5200 [14JN]

Medicaid: allow States to provide medical assistance at a residential pediatric recovery center to infants under 1 year of age with neonatal abstinence syndrome and their families (see S. 2899), S2835 [22MY] (see H.R. 6004), H4776 [5JN]

——— allow States to provide services for certain individuals with opioid use disorders in mental institutions (see H.R. 5797), H3975 [15MY]

——— allow States to provide services for certain individuals with opioid use disorders in mental institutions (H.R. 5797), consideration (see H. Res. 949), H5283 [19JN]

——— cover protections for pregnant and post-partum women while receiving inpatient treatment for a substance use disorder (see H.R. 5789), H3975 [15MY]

——— ensure coverage of inpatient treatment services furnished in mental institutions (see S. 2921), S2835 [22MY]

——— evaluate access to services and treatment for substance use disorders, telehealth services, and remote patient monitoring for pediatric populations (see S. 2910), S2835 [22MY]

——— facilitate access to State prescription drug monitoring programs (see S. 2902), S2835 [22MY]

——— impose restrictions on opioid prescriptions (see H.R. 5635), H3705 [26AP]

——— improve access to care for pregnant and postpartum women receiving substance use disorder treatment in mental institutions (see S. 2922), S2835 [22MY]

——— issue guidance to States to improve care for infants with neonatal abstinence syndrome and their parents or guardians (see S. 3429), S6142 [12SE]

——— prevent misclassification of drugs for purposes of the drug rebate program (see S. 3702), S7275 [4DE] (see H.R. 7223), H9767 [6DE]

——— provide extension of enhanced Federal medical assistance percentage for health homes for individuals with substance use disorders (see S. 3384), S5932 [23AU] (see H.R. 5810), H3976 [15MY]

——— provide for a demonstration project to increase substance use provider treatment capacity (see S. 3383), S5932 [23AU] (see H.R. 5477), H3146 [11AP]

——— provide requirements relative to use of qualified prescription drug monitoring programs and prescribing of certain controlled substances (see H.R. 5801), H3976 [15MY]

——— provide States with an option to provide medical assistance to individuals between ages of 21 and 64 for inpatient services to treat substance use disorders at certain facilities (see S. 3462), S6223 [18SE]

——— remove lifetime limits on medication-assisted treatment for substance use disorders (see S. 2898), S2835 [22MY]

——— require State plans have in place certain drug utilization review activities to receive full Federal medical assistance percentage (see H.R. 5799), H3975 [15MY]

——— require State plans to cover medication-assisted treatment (see H.R. 5802), H3976 [15MY]

——— sunset the limit on maximum rebate amount for single source drugs and innovator multiple source drugs (see H.R. 6642), H7734 [31JY]

Medicare: cover opioid treatment program services (see S. 2875), S2773 [17MY] (see H.R. 5080, 5083), H1226 [23FE] (see H.R. 5776), H3934 [11MY]

——— deliver a meaningful drug benefit and lower prescription drug prices (see H.R. 6575), H7722 [26JY]

——— encourage use of non-opioid analgesics for management of post-surgical pain (see H.R. 5809), H3976 [15MY]

——— ensure equitable payment for, and beneficiary access to, diagnostic radiopharmaceuticals under hospital outpatient prospective payment system (see H.R. 6948), H9150 [27SE]

——— establish Medicare for America program to provide comprehensive health insurance coverage for all U.S. residents (see H.R. 7339), H10336 [19DE]

——— establish part E public health plans available to everyone (see S. 2708), S2262 [18AP] (see H.R. 6117), H5200 [14JN]

——— expand access to addiction treatment in federally qualified health centers and rural health clinics (see H.R. 5769), H3929 [10MY]

——— expand eligibility for medication therapy management programs to include certain individuals who are at risk for prescription drug abuse (see H.R. 5684), H3781 [7MY]

——— expand use of telehealth services for treatment of opioid use disorder and other substance use disorders (see S. 2901), S2835 [22MY]

——— identify and notify outlier prescribers of opioids (see S. 2920), S2835 [22MY] (see H.R. 5716), H3884 [9MY]

——— include screening for potential substance use disorders and a review of any current opioid prescriptions as part of the initial preventive physical examination and the annual wellness visit (see S. 2900), S2835 [22MY]

——— prevent growth rate cliff for out-of-pocket threshold under part D (see H.R. 6563), H7721 [26JY]

——— prohibit health plans and pharmacy benefit managers from restricting pharmacies from informing individuals regarding prices for certain drugs and biologicals (see S. 2553), S1735 [14MR] (see H.R. 6144), H5284 [19JN]

——— prohibit health plans and pharmacy benefit managers from restricting pharmacies from informing individuals regarding prices for certain drugs and biologicals (S. 2553), correction in enrollment (see S. Con. Res. 49), S6388 [28SE]

——— provide coverage of methadone (see S. 2704), S2261 [18AP]

——— provide educational resources regarding opioid use and pain management as part of the ‘‘Medicare & You’’ handbook (see S. 2707), S2262 [18AP] (see H.R. 5685), H3781 [7MY]

——— provide for a combined part B and D drug out-of-pocket costs limitation (see H.R. 7001), H9406 [28SE]

——— provide for an opioid use disorder treatment demonstration program (see H.R. 5605), H3505 [24AP]

——— provide for distribution of additional residency positions to help combat the opioid crisis (see S. 2843), S2678 [15MY] (see H.R. 5818), H3976 [15MY]

——— provide for electronic prior authorization for covered part D drugs (see S. 2908), S2835 [22MY] (see H.R. 4841), H553 [18JA]

——— provide for review and adjustment of payments under outpatient prospective payment system to avoid financial incentives to use opioids instead of non-opioid alternative treatments (see H.R. 5778), H3935 [11MY] (see H.R. 6110), H5199 [14JN]

——— require Dept. of HHS to determine covered part D prescription drug prices for beneficiaries (see H.R. 6574), H7722 [26JY]

——— require Dept. of HHS to negotiate prices of prescription drugs (see H.R. 6505), H7685 [25JY]

——— require drug manufacturers to pay a rebate for certain drugs if the price of such drugs increases faster than inflation (see H.R. 5150), H1340 [1MR]

——— require drug price concessions, incentive payments, and adjustments to be included in negotiated prices at the point-of-sale under part D (see H.R. 5958), H4728 [24MY]

——— require e-prescribing for coverage under part D of prescription drugs that are controlled substances (see S. 2460), S1243 [27FE]

——— require hospitals to provide information on acquisition costs for drugs in the 340B discount drug program and total revenues received by the hospital for such drugs (see S. 2453), S1243 [27FE]

——— require Medicare Advantage and part D prescription drug plans to include information on risks associated with opioids, coverage of certain nonopioid pain treatments, and safe disposal of prescription drugs (see H.R. 5775), H3934 [11MY]

——— require Medicare Advantage and part D prescription drug plans to provide information on safe disposal of prescription drugs that are controlled substances to certain enrolled individuals (see S. 3489), S6304 [25SE] (see H.R. 5714), H3884 [9MY]

——— require prescription drug plan sponsors to establish drug management programs for at-risk beneficiaries (see H.R. 5675), H3749 [3MY]

——— require prescription drug plan sponsors to establish drug management programs for at-risk beneficiaries, electronic prior authorization for covered part D drugs, and provide for other program integrity measures (see H.R. 5773), H3934 [11MY]

——— require prescription drug plans to include information on adverse effects of opioid overutilization and of coverage of nonpharmacological therapies and nonopioid medications or devices used to treat pain (see H.R. 5686), H3781 [7MY]

——— require review of current opioid prescriptions for chronic pain and screening for opioid use disorder be included in initial preventive physical examinations (see H.R. 5798), H3975 [15MY]

——— require the Medicare Payment Advisory Commission to report on opioid payment, adverse incentives, and data (see H.R. 5723), H3884 [9MY]

——— study and report on feasibility of basing reimbursement rates for part B drugs and covered part D drugs on average prices in Organization for Economic Cooperation and Development member-states (see H.R. 6958), H9150 [27SE]

——— suspend payments by prescription drug plans and Medicare Advantage prescription drug plans pending investigation of credible allegations of fraud by pharmacies (see S. 3327), S5582 [1AU] (see H.R. 5676), H3749 [3MY]

——— waive certain telehealth requirements in the case of certain treatment of an opioid use disorder or co-occurring mental health disorder (see H.R. 5603), H3505 [24AP]

Medicare/Medicaid: help end addictions and lessen substance abuse disorders (see S. 3120), S4368 [25JN]

——— promote ability of beneficiaries to access their personal medical claim data through a mobile health record application (see H.R. 7272), H10169 [12DE]

——— provide for a demonstration program and pilot project to expand choice for inpatient psychiatric services (see H.R. 6343), H6172 [12JY]

Members of Congress: require Members to participate in random drug testing (see H. Con. Res. 135), H8170 [12SE]

Meningitis B Awareness Day: observance (see H. Res. 842), H3506 [24AP]

Mental health: strengthen parity in mental health and substance use disorder benefits (see S. 2301), S168 [11JA] (see H.R. 4778), H168 [11JA]

Mental Health Parity and Addiction Equity Act: anniversary (see S. Res. 670), S6732 [9OC]

Mexico: recognize importance of bilateral relationship with the U.S. in areas of trade, security, law enforcement, energy, economy, and culture and encourage strengthening of NAFTA (see S. Res. 371), S138 [10JA]

National Alcohol and Drug Addiction Recovery Month: observance (see S. Res. 669), S6542 [4OC]

National Institute of Minority Health and Health Disparities: submit a report to Congress on impact of opioid epidemic on minority communities (see H.R. 5616), H3574 [25AP]

National objectives: acknowledge that the War on Drugs has been a failed policy and apologize to individuals and communities victimized by this policy (see H. Res. 933), H5093 [12JN]

National Women’s Health Week: recognize importance of goal to empower young women to make informed choices about sexual activity and take effective steps to protect against HIV (see S. Res. 507), S2679 [15MY]

Native Americans: authorize a special behavioral health program for Indians (see S. 2545), S1735 [14MR]

NIH: conduct or support further comprehensive research for creation of a universal influenza vaccine (see S. 2438), S1164 [15FE] (see H.R. 5092), H1266 [26FE]

——— expand, intensify, and coordinate research and other activities relative to prenatal opioid exposure and neonatal abstinence syndrome (see H.R. 5927), H4692 [23MY]

Office of National Drug Control Policy: reauthorize, redesignate as Office of National Drug Control, and enhance authorities to improve Federal drug control efforts (see H.R. 5925), H4692 [23MY]

——— track and review federally funded drug demand reduction activities (see S. 3380), S5932 [23AU]

Office of the Director of National Intelligence: determine if Iran has used funds from sanctions relief or certain payments to sponsor terrorist organizations, for illicit narcotics activities, or military operations in Syria (see H.R. 6774), H8169 [12SE]

Orphan Drug Act: affirm importance, commend life-saving accomplishments, and recognize need and continued support for research in development of therapies, treatments, and cures for rare diseases (see S. Res. 690), S7051 [15NO] (see H. Res. 1154), H9568 [16NO]

Packaging: require improved packaging and disposal methods with respect to certain drugs (see H.R. 5687), H3781 [7MY]

Patents: prohibit avoidance of drug patent reviews regardless of sovereign immunity claims facilitated by the transfer of patents to Indian tribes (see S. 2514), S1452 [7MR]

Pharmaceuticals: clarify the orphan drug exception to the annual fee on branded prescription pharmaceutical manufacturers and importers (see H.R. 7324), H10269 [17DE]

——— prohibit biological product manufacurers from compensating biosimilar and interchangeable product companies to delay entry of biosimilar and interchangeable products into the market (see S. 3792), S7926 [19DE]

——— prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market (see S. 3792), S7926 [19DE]

Postal Service: authorize inspection of certain suspicious packages for illicit materials without a warrant (see S. 2741), S2391 [24AP]

Prematurity Research Expansion and Education for Mothers Who Deliver Infants Early (PREEMIE) Act: revise and extend (see S. 3029), S3293 [7JN] (see H.R. 6085), H5151 [13JN]

Public Health Service: report on health effects of using new psychoactive substances, including synthetic drugs (see S. 3356), S5759 [21AU]

Public welfare programs: prohibit assistance under Temporary Assistance for Needy Families Program from being accessed through an electronic benefit transfer card at stores that sell marijuana (see H.R. 5853), H4138 [16MY]

Research: encourage development and use of new antimicrobial drugs in order to treat antibiotic-resistant infections (see S. 3787), S7926 [19DE]

Russia: condemn destabilizing activities and call on Fédération Internationale de Football Association (FIFA) to explain why it continues to plan to hold the World Cup in Russia based on such activities (see H. Res. 926), H4849 [6JN]

SEC: require certain additional disclosure by pharmaceutical companies relative to the Tax Cuts and Jobs Act (see S. 2885), S2773 [17MY]

Social Security: expand scope of transparency reporting requirements on ownership or investment interests of health care providers and others, and increase penalties for violating such requirements (see S. 3770), S7790 [18DE]

——— reform (see H.R. 7195), H9743 [29NO]

——— require drug and medical device companies to include information on payments made to physician assistants, nurse practitioners, and other advance practice nurses in certain transparency reports (see S. 2891), S2834 [22MY]

Sports: establish criminal penalties and civil remedies for doping fraud violations at major international competitions (see H.R. 6067), H5093 [12JN]

——— establish criminal penalties and civil remedies for doping fraud violations at major international competitions and require sharing of information with U.S. Anti-Doping Agency (see S. 3790), S7926 [19DE]

States: protect States and individuals in States that have laws which permit the use of marijuana (see H.R. 4779), H168 [11JA]

Taxation: authorize designation of additional taxable vaccines (see S. 3253), S5108 [19JY] (see H.R. 4993), H1074 [8FE]

——— include certain over-the-counter medical products as qualified medical expenses (see H.R. 6199), H5580 [22JN]

——— include certain over-the-counter medical products as qualified medical expenses (H.R. 6199), consideration (see H. Res. 1012), H6648 [23JY]

——— prohibit deduction for prescription drug advertising and promotional expenses (see S. 2478), S1316 [1MR]

U.S. Customs and Border Protection: provide for processing of certain international mail shipments and advance electronic information on international mail shipments to target opioid shipments (see S. 3057), S3760 [12JN] (see H.R. 5788), H3975 [15MY]

——— provide for processing of certain international mail shipments and advance electronic information on international mail shipments to target opioid shipments (H.R. 5788), consideration (see H. Res. 934), H5092 [12JN]

U.S. Sentencing Commission: establish penalties for causing environmental damage while cultivating marijuana or other controlled substances on Federal lands or trespassing on private property (see H.R. 7018), H9414 [2OC]

Venezuela: provide humanitarian relief, advance a constitutional and democratic solution to political crisis, address economic reconstruction, and combat public corruption, narcotics trafficking, and money laundering (see S. 3486), S6277 [24SE] (see H.R. 7245), H9820 [10DE]

World Hepatitis Day: observance (see S. Res. 600), S5518 [31JY] (see H. Res. 1038), H7725 [26JY]

World Tuberculosis Day: support goals (see S. Res. 437), S1790 [19MR]

Cost Estimates

Border Tunnel Task Force Act (H.R. 6740): CBO, E1340 [28SE]

Joint Task Force To Combat Opioid Trafficking Act (H.R. 5762): CBO, E962 [3JY]

E-Mails

Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: Advocates for Opioid Recovery (organization), H9252 [28SE]

Essays

State of the Union: Elizabeth Toensing, S649 [6FE]

——— Lillian Cazayoux, S606 [5FE]

——— Paige Greenia, S607 [5FE]

Letters

Allow local communities to prevent location of sober living homes in residential neighborhoods: Ada Thornton, E1369 [5OC]

——— Alan Osterhout, E1394 [12OC]

——— Albert Francis, E1383 [9OC]

——— Amy Santos, E1479 [30OC]

——— Anne DeBie, E1368 [5OC]

——— Bobby Taylor, E1479 [30OC]

——— Bridget Kaub, E1478 [30OC]

——— Bruce Wareh, E1488 [2NO]

——— Catherine Young, E1423 [19OC]

——— Colleen Pilz, E1410 [16OC]

——— Diane Babcock, E1368 [5OC]

——— Donald Haddock, E1441 [23OC]

——— Donna Segeberg, E1442 [23OC]

——— Doug Daniels, E1479 [30OC]

——— Edward Skelton, E1383 [9OC]

——— Erin Blancett, E1384 [9OC]

——— Gina MacDonald, E1383 [9OC]

——— Gina O’Brien, E1442 [23OC]

——— Gina Walters, E1424 [19OC], E1442 [23OC]

——— Graham Shute, E1424 [19OC]

——— James Russell, E1368 [5OC]

——— Jan McAllister, E1442 [23OC]

——— Janet Cardenas, E1384 [9OC]

——— Jeanne Kulpinski, E1488 [2NO]

——— Jeffrey Frei, E1409 [16OC]

——— Jennifer Shields, E1369 [5OC]

——— John Sims, E1394 [12OC]

——— Josh Juroe, E1369 [5OC]

——— Joti Ghuman, E1383 [9OC]

——— Karen Pesko, E1423 [19OC]

——— Keith Frainie, E1409 [16OC]

——— Kristen Sandberg, E1409 [16OC]

——— Kristine Koch, E1424 [19OC]

——— Lauri McMillen, E1410 [16OC]

——— Leslie Wannall, E1395 [12OC]

——— Less Tait, E1487 [2NO]

——— Linda Hicks, E1423 [19OC]

——— Manuela Almeida, E1394 [12OC]

——— Marilyn Brooks, E1409 [16OC]

——— Monte Kay Yohr, E1394 [12OC]

——— Opjit Ghuman, E1384 [9OC]

——— Patricia Anne Quintana, E1368 [5OC]

——— Paul Stary, E1441 [23OC]

——— Preeti Ghuman, E1487 [2NO]

——— Roberta Lewis, E1442 [23OC]

——— Robin Grisham, E1369 [5OC]

——— Robin Rustan, E1442 [23OC]

——— Robyn Hubbard, E1442 [23OC]

——— Sean Croson, E1395 [12OC]

——— Sheila Cimini, E1368 [5OC]

——— Shelley, Buker, E1396 [12OC]

——— Sherrie Wolfe, E1395 [12OC]

——— Stephanie A. Larcome, E1368 [5OC]

——— Steve Treskes, E1424 [19OC]

——— Tony Kaz, E1395 [12OC]

——— Virginia McCoy, E1384 [9OC]

Border Security and Immigration Reform Act: Representative Conaway, Committee on Agriculture (House), H5482 [21JN]

——— Representative Goodlatte, Committee on the Judiciary (House), H5482 [21JN]

——— Representative McCaul, Committee on Homeland Security (House), H5482 [21JN]

Coordinated Response Through Interagency Strategy and Information Sharing (CRISIS) Act: Representative Frelinghuysen, Committee on Appropriations (House), H5322 [20JN]

——— Representative Gowdy, Committee on Oversight and Government Reform (House), H5321, H5322 [20JN]

——— Representative Nunes, Committee on Intelligence (House, Select), H5322 [20JN]

——— Representative Royce, Committee on Foreign Affairs (House), H5321 [20JN]

Dept. of Homeland Security Biometric Identification Transnational Migration Alert Program establishment: several civil liberties and immigration law organizations, H7788 [4SE]

FDA user fee programs relative to new animal drugs and generic new animal drugs reauthorization: Scott Gottlieb and Steve Solomon, FDA, S5472 [31JY]

Formerly Incarcerated Reenter Society Transformed Safely Transitioning Every Person (FIRST STEP) Act: Marc Mauer, Sentencing Project (organization), H4317 [22MY]

——— several organizations, H4316 [22MY]

Know the Lowest Price Act: David Mitchell, Patients for Affordable Drugs, Inc., S2665 [15MY]

——— Karry K. La Violette, National Community Pharmacists Association, H8798 [25SE]

——— several health organizations, S2666 [15MY]

——— Tom O’Donnell, National Association of Chain Drug Stores, H8798 [25SE]

National policy to provide health care and reform insurance procedures: Senator Alexander, Committee on Health, Education, Labor, and Pensions (Senate), S7393 [11DE]

Opioid drug abuse prevention legislation: Representative Kevin Brady, Committee on Ways and Means (House), H5033, H5062, H5065 [12JN], H5238, H5241, H5248, H5252, H5256, H5257, H5260, H5262, H5264 [19JN]

——— Representative Walden, Committee on Energy and Commerce (House), H5033, H5062, H5065 [12JN], H5237, H5241, H5248, H5252, H5256, H5258, H5260, H5262, H5264 [19JN]

Overdose Prevention and Patient Safety Act: Partnerhship To Amend 42 CFR Part 2 (organization), H5332 [20JN]

——— several organizations, H5331 [20JN]

Patient Right To Know Drug Prices Act: David Mitchell, Patients for Affordable Drugs, Inc., S2665 [15MY]

——— Karry K. La Violette, National Community Pharmacists Association, H8798 [25SE]

——— Saul Levin, American Psychiatric Association, H8798 [25SE]

——— several health organizations, S2666 [15MY]

——— Thomas E. Menighan, American Pharmacists Association, S2665 [15MY]

Restoring Community Oversight of Sober Living Homes Act: Catherine Orlando, E1441 [23OC]

——— Deborah Wilder, E1409 [16OC]

——— Deder Barnes, E1424 [19OC]

——— James Etheredge, E1441 [23OC]

Right To Try Act: Andrew McFadyen, Isaac Foundation, H1740 [21MR]

——— several organizations, H4358 [22MY]

Securing Opioids and Unused Narcotics With Deliberate (SOUND) Disposal and Packaging Act: William Simpson, DisposeRX, Inc., H5236 [19JN]

Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: Carol Keehan, Catholic Health Association of the U.S., H9252 [28SE]

——— Corporate Health Care Coalition, H9250 [28SE]

——— James A. Klein, American Benefits Council, H9251 [28SE]

——— Peter Morris, Alex Dodd, David White, Jay Higham, and John Steinbrun, Opioid Treatment Program Consortium, H5561 [22JN]

——— several organizations, H9253 [28SE]

——— Suzanne P. Clark, U.S. Chamber of Commerce, H9252 [28SE]

——— Tom Van Coverden, National Association of Community Health Centers, H9251 [28SE]

Support location of sober living homes in residential neighborhoods: Toni Stein, E1442 [23OC]

Synthetics Trafficking and Overdose Prevention (STOP) Act: Representative Gowdy, Committee on Oversight and Government Reform (House), H5167 [14JN]

——— Representative Kevin Brady, Committee on Ways and Means (House), H5167 [14JN]

——— Representative McCaul, Committee on Homeland Security (House), H5167 [14JN]

Lists

Organizations opposed to H.R. 5247, Right To Try Act, H1525 [13MR], H1742 [21MR]

Organizations supporting H.R. 6, Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, H9243 [28SE]

Messages

Budget of the U.S. Government for Fiscal Year 2019: President Trump, S870 [12FE], H1080 [13FE]

Motions

Dept. of HHS: ensure doctors have access to patient treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (H.R. 6082), H5333 [20JN]

Dept. of Homeland Security: strengthen border security and increase resources for enforcement of immigration laws (H.R. 6136), H5765 [27JN]

Diseases and disorders: authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur within a matter of months, or with another eligible illness (H.R. 5247), H1746 [21MR]

Drug abuse: provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), H5567 [22JN]

Health: authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), H4363 [22MY]

Medicaid: allow States to provide services for certain individuals with opioid use disorders in mental institutions (H.R. 5797), H5342 [20JN]

Press releases

Know the Lowest Price Act: CVS Health Corp., S2666 [15MY]

——— Express Scripts Holding Co., S2666 [15MY]

Patient Right To Know Drug Prices Act: CVS Health Corp., S2666 [15MY]

——— Express Scripts Holding Co., S2666 [15MY]

——— Pharmaceutical Care Management Association, S2666 [15MY]

Remarks in House

Africa: increase efforts to combat drug-resistant tuberculosis in southern Africa, E1016 [16JY]

American Medical Marijuana Physicians Association: tribute, E382 [29MR]

Appalachian Regional Commission: allow funding to be used to address impacts of opioid addiction on workforce development and economic growth in Appalachia, H9249 [28SE]

——— allow funding to be used to address impacts of opioid addiction on workforce development and economic growth in Appalachia (H.R. 5294), H5115–H5117 [13JN]

Aurora, CO: tribute to Comitis Crisis Center, E1498 [6NO]

Barton, Representative: appreciation of opportunity to serve, H10098–H10101 [11DE]

Better Life in Recovery (nonprofit organization): tribute, E1211 [5SE]

Block, Timothy M.: National Academy of Inventors, Inc., Fellows Program inductee, H420 [17JA], H485 [18JA]

CDC: carry out certain activities to prevent controlled substances overdoses (H.R. 5812), H5071–H5074 [12JN]

——— reauthorize and expand a program of surveillance and education regarding infections associated with injection drug use, H5518 [22JN]

——— reauthorize and expand a program of surveillance and education regarding infections associated with injection drug use (H.R. 5353), H5059, H5060 [12JN]

Centers for Medicare & Medicaid Services: provide for an action plan to prevent opioid addictions and enhance access to medication-assisted treatment (H.R. 5590), H5247–H5249 [19JN]

Chatham County, GA: tribute to Chatham-Savannah Counter Narcotics Team, H3729 [27AP]

Cincinnati (OH) Enquirer: Pulitzer Prize recipient for local reporting, E674 [17MY]

Committee on Foreign Affairs (House): Subcommittee on Africa, Global Health, Global Human Rights, and International Organizations hearing on Global Health Supply Chain Management—Lessons Learned and Ways Forward, E682 [18MY]

Crime: establish criminal penalties for unlawful payments for referrals to recovery homes and clinical treatment facilities, H9244, H9249 [28SE]

Crime Stoppers Global Solutions (organization): tribute, E1652 [12DE]

DEA: allow for prescription of medication-assisted treatment and other controlled substances via telemedicine to improve access to opioid addiction treatment, H9248 [28SE]

——— allow for prescription of medication-assisted treatment and other controlled substances via telemedicine to improve access to opioid addiction treatment (H.R. 5483), H5060, H5061 [12JN], E1537 [16NO]

——— clarify definition of ‘‘imminent danger to the public health or safety’’ to restore authority to suspend a pharmaceutical distributor’s license under certain circumstances (H.R. 4079), E888 [21JN]

——— develop training materials covering circumstances when a pharmacist may decline to fill a prescription due to suspicion the prescription is fraudulent, forged, or indicative of abuse (H.R. 4275), H5066, H5067 [12JN]

——— report on the sale of lawful and unlawful controlled substance analogues over the Internet, H5218 [15JN]

Democratic Party: national agenda, H8176 [13SE], H9514 [14NO]

Dept. of Defense: monitor medication prescribing practices for treatment of post-traumatic stress disorder, H4565 [22MY]

——— provide flexibility to provide technical assistance by U.S. military women to military women in other countries combating violence as a weapon of war, terrorism, human trafficking, or narcotics trafficking, H5738, H5739 [26JN]

Dept. of HHS: address use of opioids and substance use disorders relative to pregnant women and babies (H.R. 5492), H3434 [18AP]

——— amend and reauthorize National All Schedules Prescription Electronic Reporting (NASPER) Grant Program, H3436 [18AP]

——— appoint a Federal Coordinator to coordinate opioid abuse reduction programs, serve as a liaison to State and local opioid reduction activities, and establish an electronic database on opioid abuse information, H9246 [28SE]

——— appoint a Federal Coordinator to coordinate opioid abuse reduction programs, serve as a liaison to State and local opioid reduction activities, and establish an electronic database on opioid abuse information (H.R. 4284), H5034–H5036 [12JN]

——— appropriate funds for State Targeted Response to the Opioid Crisis Grants (H.R. 3495), H5110 [13JN]

——— authorize a loan repayment program for substance use disorder treatment employees (H.R. 5102), H5045–H5047 [12JN], E976 [6JY]

——— authorize certain substance abuse recovery services grants to be used to establish regional technical assistance centers (H.R. 5587), H5069–H5071 [12JN], E974 [6JY]

——— authorize Substance Abuse and Mental Health Services Administration development of best practices for recovery residences that promote sustained recovery from substance use disorders (H.R. 4684), H5036–H5038 [12JN], E971 [6JY]

——— conduct a demonstration program to test alternative pain management protocols to limit use of opioids in emergency departments (H.R. 5197), H5067–H5069 [12JN], H5157 [14JN], E975 [6JY]

——— conduct a study and submit a report on barriers to accessing abuse-deterrent opioid formulations for certain Medicare enrollees (H.R. 5582), H5061–H5063 [12JN]

——— develop and disseminate model training programs for substance use disorder treatment records and study patient experiences in substance use treatment programs to assess appropriate levels of privacy protections, H5334, H5335 [20JN]

——— develop guidance on pain management and prevention of opioid use disorder for hospitals receiving payments under Medicare (H.R. 5774), H5254–H5256 [19JN]

——— disseminate resources to early childhood care and education providers working with young children on ways to recognize and respond to children who may be impacted by trauma related to substance abuse, H9249 [28SE]

——— disseminate resources to early childhood care and education providers working with young children on ways to recognize and respond to children who may be impacted by trauma related to substance abuse (H.R. 5889), H5123–H5125 [13JN], H5156 [14JN]

——— ensure doctors have access to patient treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (H.R. 6082), H5325–H5335 [20JN], E876 [20JN]

——— ensure doctors have access to patient treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (H.R. 6082), consideration (H. Res. 949), H5294–H5304 [20JN], E901 [22JN]

——— ensure doctors have access to patient treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records (H.R. 6082), motion to recommit, H5334, H5335 [20JN]

——— ensure that federally-funded programs and activities to prevent or treat mental health or substance use disorders are evidence-based (H.R. 5272), H5053–H5055 [12JN]

——— establish a grant program to create comprehensive opioid recovery centers (H.R. 5327), H3434 [18AP], H5026, H5055–H5057 [12JN]

——— establish a pilot program to help individuals in recovery from a substance use disorder transition from treatment to independent living and the workforce, H9248 [28SE]

——— issue guidance relative to expedited approval of certain drugs, H5297 [20JN], H5512, H5516–H5518 [22JN]

——— issue guidelines for prescribing naloxone, H5565, H5566 [22JN]

——— nullify certain contractual provisions prohibiting or penalizing a pharmacist’s disclosure of availability of equivalent alternative drugs or methods of purchasing less expensive drugs (H.R. 5343), H8796 [25SE]

——— provide assistance to States in complying with and implementing child abuse and neglect prevention and treatment programs to promote better protections for young children and family-centered responses (H.R. 5890), H5125–H5127 [13JN], H5156, H5158 [14JN]

——— provide coordinated care to patients who have experienced a non-fatal overdose after emergency room discharge (H.R. 5176), H5026, H5047–H5049 [12JN]

——— provide for opioid quality measures development and a technical expert panel on reducing surgical setting opioid use and data collection on perioperative opioid use (H.R. 5774), H5254–H5256 [19JN]

——— provide for regional centers of excellence in substance use disorder education (H.R. 5261), H5052, H5053 [12JN]

——— provide for sharing of health information concerning an individual’s substance abuse history and treatment by certain entities (H.R. 5009), H3435 [18AP], H5042, H5043 [12JN]

——— provide grants for eligible entities to provide technical assistance to outlier prescribers of opioids (H.R. 5796), H5237–H5239 [19JN]

——— provide greater transparency of discounts provided by drug manufacturers by requiring Pharmacy Benefit Managers to reimburse community pharamacists at the same rate as high volume box stores, H9541 [16NO]

——— provide research on, and recommendations for, opioid prescribing practices for pregnant women, H5564, H5565 [22JN]

——— provide research on, and recommendations for, opioid prescribing practices for pregnant women (H.R. 5646), H3710 [27AP]

——— report on extent to which certain Medicare Advantage plans include supplemental health care benefits designed to treat or prevent substance use disorders, H5252, H5253 [19JN]

——— require prescribers to complete continuing medical education courses on potential dangers and risks of prescribing opioids (H.R. 5581), H3589 [26AP]

——— study and submit to Congress a report recommending how to improve use of non-opioid treatments for acute and chronic pain management for individuals under Medicare, H9249 [28SE]

——— survey organizations that provide substance use treatment services and submit plan to Congress to appropriate resources to address inadequacies in services or funding identified in survey, H5566, H5567 [22JN]

——— update or issue one or more guidances addressing alternative methods for data collection on opioid sparing and inclusion of such data in product labeling (H.R. 5473), H5030–H5032 [12JN]

Dept. of Homeland Security: establish Border Tunnel Task Forces (H.R. 6740), H8748–H8750 [25SE]

——— establish joint task force to integrate border security operations to detect, interdict, disrupt, and prevent narcotics such as fentanyl and other synthetic opioids from entering U.S. (H.R. 5762), H5267–H5269 [19JN], E870 [20JN]

——— improve ability of U.S. Customs and Border Protection to interdict fentanyl, other synthetic opioids, narcotics, and psychoactive substances illegally imported into the U.S. (H.R. 2142), E870 [20JN]

——— reauthorize the Border Enforcement Security Task Force program (H.R. 2281), H7787 [4SE]

——— strengthen border security and increase resources for enforcement of immigration laws, H3881 [9MY], H9579 [27NO], H9753, H9756 [30NO]

——— strengthen border security and increase resources for enforcement of immigration laws (H.R. 6136), H5376, H5377, H5450–H5488, H5504 [21JN], H5510, H5573–H5576 [22JN], H5761, H5762, H5764 [27JN], H5970 [28JN], H6489 [18JY], E883 [21JN], E933 [27JN]

——— strengthen border security and increase resources for enforcement of immigration laws (H.R. 6136), consideration (H. Res. 953), H5438–H5447 [21JN]

——— strengthen border security and increase resources for enforcement of immigration laws (H.R. 6136), motion to recommit, H5765 [27JN]

——— support officers and employees of U.S. Immigration and Customs Enforcement and denounce efforts to abolish agency, H6461 [17JY]

——— support officers and employees of U.S. Immigration and Customs Enforcement and denounce efforts to abolish agency (H. Res. 990), H6486–H6493 [18JY], H6562, H6574–H6577 [19JY], H7148 [24JY], E1049 [23JY]

Dept. of HUD: clarify applicability of the Fair Housing Act to recovery facilities to allow local communities to prevent location of sober living homes in residential neighborhoods (H.R. 5724), H3843 [9MY], H5182 [14JN], E1368 [5OC], E1383 [9OC], E1394 [12OC], E1409 [16OC], E1423 [19OC], E1441 [23OC], E1478 [30OC], E1487 [2NO]

——— ensure that tribal housing authorities are designated as eligible entities to receive vouchers and that selection criteria for awarding vouchers reflects impact that opioids are having in tribal communities, H5182, H5183 [14JN]

——— remove requirement to include recommendations for further continuation and expansion of the voucher program in a report to Congress, H5183 [14JN]

——— require eligible entities to prove that supportive housing facilities have local government authorization to operate, H5182 [14JN]

——— set aside section 8 housing vouchers for supportive and transitional housing for individuals recovering from opioid use disorders (H.R. 5735), H5001 [8JN], H5172–H5183 [14JN]

——— set aside section 8 housing vouchers for supportive and transitional housing for individuals recovering from opioid use disorders (H.R. 5735), consideration (H. Res. 934), H5107–H5115 [13JN], E841 [14JN]

Dept. of Justice: establish a national pharmaceutical stewardship program to facilitate collection and disposal of prescription medications (H.R. 4199), H3825 [8MY]

——— prohibit Federal prosecution of individuals using medical or recreational marijuana in States with legalized marijuana (H.R. 5050), E193 [15FE]

——— provide for programs to help reduce the risk that prisoners will recidivate upon release from prison (H.R. 5682), H4302–H4319 [22MY], H7929 [7SE]

——— reauthorize Comprehensive Opioid Abuse Grant Program (H.R. 6029), H5121–H5123 [13JN]

——— rescission of policy placing a low priority on Federal enforcement of marijuana laws in States with legalized marijuana, H21 [9JA], H96 [10JA], H420, H421, H471–H475 [17JA]

Dept. of Labor: establish an Advisory Committee on Opioids and the Workplace (H.R. 5892), H5129–H5131 [13JN], H5156 [14JN]

Dept. of the Treasury: allow for use of certain foreign assets to satisfy certain judgments against terrorist parties, H6617, H6618 [23JY]

Dept. of Veterans Affairs: create an opioid abuse health care kit for community health centers, H4986, H4987 [8JN]

——— ensure health care providers at VA medical facilities complete a continuing education course in pain management, H4987 [8JN]

——— enter into memorandum of understanding with a national network of State-based prescription monitoring programs under which departmental health care providers shall query such network, H4044 [16MY]

——— enter into memorandum of understanding with a national network of State-based prescription monitoring programs under which departmental health care providers shall query such network (H.R. 3832), H4250, H4251 [21MY]

——— improve Medical Surgical Prime Vendor program by using multiple regional prime vendors and medical professionals with relevant expertise to develop the medical-surgical formulary, H9800 [10DE]

——— improve Medical Surgical Prime Vendor program by using multiple regional prime vendors and medical professionals with relevant expertise to develop the medical-surgical formulary (H.R. 5418), H4257, H4258 [21MY]

Diseases and disorders: authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur within a matter of months, or with another eligible illness (H.R. 5247), H1521–H1529, H1530 [13MR], H1738–H1750 [21MR]

——— authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur within a matter of months, or with another eligible illness (H.R. 5247), motion to recommit, H1747, H1748 [21MR]

——— authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur within months, or with another eligible illness (H.R. 5247), consideration (H. Res. 787), H1704–H1712 [20MR]

——— require FDA guidance relative to investigational drug use by eligible patients, provide liability protection for facilitators of investigational treatments and increase transparency of number of such treatments, H1747, H1748 [21MR]

Drug abuse: address fentanyl abuse epidemic, E1222 [7SE]

——— address opioid drug abuse epidemic by securing the southern border, H5667 [26JN], H10326, H10327 [19DE]

——— address prescription opioid and heroin abuse, H3432–H3436 [18AP], H3565–H3567 [25AP], H5026, H5028 [12JN], H5099, H5102, H5103, H5105, H5112, H5113, H5140 [13JN], H5156, H5157, H5158, H5159, H5161, H5162, H5163, H5186 [14JN], H5221 [15JN], H5230 [19JN], H5663, H5664 [26JN], H5755 [27JN], H7692 [26JY]

——— establish an interagency task force to improve Federal response to families impacted by substance abuse disorders (H.R. 5891), H5127–H5129 [13JN], H5156 [14JN]

——— improve ability to address synthetic opioid epidemic (H.R. 1781), H544 [18JA]

——— increase State funding for response to opioid misuse crisis and research on addiction and pain relative to substance misuse crisis (H.R. 4501), H5299 [20JN]

——— making appropriations to address heroin and opioid drug abuse epidemic, H607 [21JA], H2031 [22MR]

——— making appropriations to address heroin and opioid drug abuse epidemic (H.R. 4938), H792, H793 [6FE]

——— provide assistance to States and localities affected by the opioid epidemic and improve delivery of essential services to individuals with substance use disorders and their families (H.R. 5545), H5113 [13JN], H5323 [20JN]

——— provide for additional flexibility relative to medication-assisted treatment for opioid use disorders, H5512, H5514 [22JN]

——— provide for additional residency positions to help combat opioid crisis, increase funding for opioid abuse crisis, and prohibit delays of generic drugs and biosimilar biological products, H5570 [22JN], E905 [25JN]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), H5380 [21JN], H5511–H5572 [22JN], H5755 [27JN], H9553 [16NO], E902 [22JN], E950 [28JN]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), concur in Senate amendment (H. Res. 1099), H9156, H9174–H9255 [28SE]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), consideration (H. Res. 949), H5294–H5304 [20JN], E901 [22JN]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), motion to recommit, H5570 [22JN], E905 [25JN]

Ellenville, NY: tribute to Ellenville Regional Hospital for initiative to combat opioid abuse, E1437 [23OC]

Fallingston, PA: tribute to Pennsbury School District Addiction and Mental Health Task Force, H1182 [15FE]

FDA: allow for detention, refusal, and destruction of certain drugs offered for importation (H.R. 5752), H5117–H5119 [13JN]

——— amend policies relative to postapproval study requirements for certain controlled substances (H.R. 5811), H5243, H5244 [19JN]

——— clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (H.R. 5333), H6227–H6237 [16JY]

——— clarify regulatory framework relative to certain nonprescription drugs that are marketed without an approved new drug application (H.R. 7328), H10366–H10393 [20DE]

——— deter opioid abuse and addiction through development of high-quality, evidence-based opioid analgesic prescribing guidelines, H5563, H5564 [22JN]

——— hold pharmaceutical companies accountable for illegal marketing and distribution of opioid products and for their role in creating and exacerbating the opioid epidemic (S. 2691), H3588 [26AP]

——— improve expanded access program to allow patients access to experimental life-saving drugs, H4364, H4365 [22MY]

——— preserve effectiveness of medically important antimicrobials used in treatment of animal diseases in order to minimize development of antibiotic-resistant bacteria (H.R. 1587), H3825 [8MY]

——— reauthorize user fee programs relative to new animal drugs and generic new animal drugs (H.R. 5554), H6237–H6242 [16JY]

——— strengthen authorities to address counterfeit drugs, illegal and synthetic opioids, and opioid-like substances (H.R. 5228), H5049–H5052 [12JN], H5118 [13JN], E972 [6JY]

Federal aid programs: provide access to medication-assisted treatment programs to reduce opioid addiction overdoses and relapses, H5522 [22JN]

Forest Service: combating illegal marijuana growing operations funding through reductions in forest and rangeland research account funding, H6454, H6455 [17JY]

FTC: ensure mergers involving pharmaceutical companies do not lead to increases in prescription drug prices, H3856, H3857 [9MY]

GAO: conduct study on how virtual currencies and online marketplaces are used to facilitate sex and drug trafficking, H6310, H6311 [17JY]

——— conduct study on how virtual currencies and online marketplaces are used to facilitate sex and drug trafficking (H.R. 6069), H5589, H5590 [25JN]

——— study feasibility of establishing and maintaining automated system that tracks prescription drug prices (H.R. 6593), E1096 [26JY]

Government regulations: clarify how synthetic drugs known as analogues are to be regulated (H.R. 2851), H5001 [8JN], H5099 [13JN], H5204–H5221 [15JN]

——— clarify how synthetic drugs known as analogues are to be regulated (H.R. 2851), consideration (H. Res. 934), H5107–H5115 [13JN], E841 [14JN]

——— define what constitutes a controlled substance analogue, clarify temporary import and distribution controls of certain synthetic drugs, and ensure Federal researchers can continue controlled substance research, H5215, H5216 [15JN]

——— specify the factors used to determine whether a controlled substance analogue is intended for human consumption, H5218–H5220 [15JN]

Hankins, Barbara: California 3d Congressional District Woman of the Year award recipient, E1466 [26OC]

Health: authorize, develop, and implement a coordinated tracking system of federally-funded initiatives and grant programs for substance abuse treatment, prevention, and enforcement, H5321, H5324, H5325 [20JN], H9249 [28SE]

——— authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (H.R. 878), H685 [30JA], H1647 [15MR]

——— authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), H485 [18JA], H4355–H4366 [22MY], H4682 [23MY], E751 [29MY]

——— authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), consideration (H. Res. 905), H4292–H4301 [22MY]

——— authorize use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law (S. 204), motion to recommit, H4364, H4365 [22MY]

Health care professionals: authority of non-physician providers to prescribe buprenorphine for opioid use disorders, H5297 [20JN]

——— authorize employees of a hospice program to handle controlled substances in the residence of a deceased hospice patient to assist in disposal (H.R. 5041), H5043–H5045 [12JN], H5163 [14JN]

——— prohibit expansion of classes of health care workers who are authorized to dispense narcotics for narcotic treatment, H5561, H5562 [22JN]

Hogar CREA, Inc.: anniversary, H3843 [9MY]

Housing: provide that an individual who uses marijuana in compliance with State law may not be denied occupancy of federally assisted housing (H.R. 6152), E865 [19JN]

Immigration: fund construction of southern border wall, ensure compliance with Federal immigration law, and combat sanctuary cities, transnational gangs, human trafficking, and drugs, H9556 [16NO]

——— impact of illegal immigration on violent crime, H5497 [21JN]

——— secure the border between the U.S. and Mexico, H1107 [13FE], H1134 [14FE], H3101 [11AP], H6108 [11JY], H9807 [10DE]

——— use of budget reconciliation to establish a Border Wall and Security Trust Fund (H.R. 7073), H9739 [29NO]

Indianapolis, IN: anniversary of Wheeler Mission Ministries, E1331 [28SE]

Insurance: ensure that health insurance issuers and group health plans do not prohibit pharmacy providers from providing certain information to enrollees (S. 2554), H8795–H8799 [25SE]

——— prohibit health insurance issuers, group health plans, Medicare Advantage organizations, and prescription drug plan sponsors from limiting drug price information a pharmacy may give to a consumer (H.R. 6733), H8796 [25SE]

Jenkins, Representative Evan H.: appreciation of opportunity to serve, H9095 [27SE]

Kaitlin Murphy Foundation: tribute, H6045 [11JY]

Law enforcement: address trafficking of illicit fentanyl and urge Mexico and China to assist in stopping such trafficking, H543, H544 [18JA]

——— criminal justice reform, H5639 [25JN]

Marijuana: authorize evidence based report analyzing current marijuana policies and their effects on communities, H6637 [23JY]

——— end Federal ban of medical marijuana, allow importation of certain derivatives, allow banks to work with medical marijuana businesses, enable medicinal research, and allow prescription to veterans, H3501–H3503 [24AP]

——— provide for legitimate use of medicinal marijuana in accordance with State laws, H21 [9JA], H471–H475 [17JA]

——— reschedule marijuana under the Controlled Substances Act, H474 [17JA]

Medicaid: allow State to determine level of care and length of stay for certain individuals with opioid use disorders in mental institutions based on State criteria, H5341, H5342 [20JN]

——— allow States to provide medical assistance at a residential pediatric recovery center to infants under 1 year of age with neonatal abstinence syndrome and their families, H9156 [28SE]

——— allow States to provide services for certain individuals with opioid use disorders in mental institutions, H5515 [22JN], H9249 [28SE]

——— allow States to provide services for certain individuals with opioid use disorders in mental institutions (H.R. 5797), H5335–H5345 [20JN], E876 [20JN], E907 [25JN]

——— allow States to provide services for certain individuals with opioid use disorders in mental institutions (H.R. 5797), consideration (H. Res. 949), H5294–H5304 [20JN], E901 [22JN]

——— allow States to provide services for certain individuals with opioid use disorders in mental institutions (H.R. 5797), motion to recommit, H5343 [20JN]

——— allow States to provide services for certain individuals with opioid use disorders in mental institutions if the State expands Medicaid, H5343 [20JN]

——— expand services for certain individuals with opioid use disorders in mental institutions to include individuals suffering from cocaine use disorder, H5339, H5340 [20JN]

——— prevent misclassification of drugs for purposes of the drug rebate program, H10050, H10051 [11DE]

——— provide requirements relative to use of qualified prescription drug monitoring programs and prescribing of certain controlled substances (H.R. 5801), H5245–H5247 [19JN]

——— report number of patients in mental institutions suffering with co-occuring disorders and provide information on community care access for individuals suffering from mental illness other than substance abuse, H5340, H5341 [20JN]

Medicare: cover opioid treatment program services, H5520 [22JN]

——— eliminate gap in coverage of prescription drug benefit, H1078 [13FE]

——— encourage use of non-opioid analgesics for management of post-surgical pain, H5512, H5513, H5514 [22JN]

——— establish Universal Medicare Program to provide comprehensive health insurance coverage for all U.S. residents (S. 1804), H9808 [10DE]

——— expand access to addiction treatment in federally qualified health centers and rural health clinics, H5252, H5253 [19JN]

——— expand eligibility for medication therapy management programs to include certain individuals who are at risk for prescription drug abuse, H5260, H5261 [19JN]

——— identify and notify outlier prescribers of opioids, H5260, H5261 [19JN]

——— prohibit health plans and pharmacy benefit managers from restricting pharmacies from informing individuals regarding prices for certain drugs and biologicals (S. 2553), H8796–H8801 [25SE]

——— provide educational resources regarding opioid use and pain management as part of the ‘‘Medicare & You’’ handbook (H.R. 5685), H5064–H5066 [12JN]

——— provide for an opioid use disorder treatment demonstration program (H.R. 5605), H5239–H5243 [19JN]

——— provide for electronic prior authorization for covered part D drugs, H5260, H5261 [19JN]

——— provide for review and adjustment of payments under outpatient prospective payment system to avoid financial incentives to use opioids instead of non-opioid alternative treatments, E870 [20JN]

——— provide for review and adjustment of payments under outpatient prospective payment system to avoid financial incentives to use opioids instead of non-opioid alternative treatments (H.R. 6110), H5249–H5254 [19JN], E870 [20JN]

——— require e-prescribing for coverage under part D of prescription drugs that are controlled substances, H5512, H5514 [22JN]

——— require Medicare Advantage and part D prescription drug plans to include information on risks associated with opioids, coverage of certain nonopioid pain treatments, and safe disposal of prescription drugs (H.R. 5775), H5256–H5258 [19JN], E877 [20JN]

——— require Medicare Advantage and part D prescription drug plans to provide information on safe disposal of prescription drugs that are controlled substances to certain enrolled individuals, H5258 [19JN], E877 [20JN]

——— require prescription drug plan sponsors to establish drug management programs for at-risk beneficiaries, H5520 [22JN]

——— require prescription drug plan sponsors to establish drug management programs for at-risk beneficiaries, electronic prior authorization for covered part D drugs, and provide for other program integrity measures, E902 [22JN]

——— require prescription drug plan sponsors to establish drug management programs for at-risk beneficiaries, electronic prior authorization for covered part D drugs, and provide for other program integrity measures (H.R. 5773), H5103 [13JN], H5258–H5261 [19JN]

——— require prescription drug plans to include information on adverse effects of opioid overutilization and of coverage of nonpharmacological therapies and nonopioid medications or devices used to treat pain, H5257, H5258 [19JN], E877 [20JN]

——— require review of current opioid prescriptions for chronic pain and screening for opioid use disorder be included in initial preventive physical examinations, H5514 [22JN]

——— require the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries, H1647 [15MR]

——— require the Medicare Payment Advisory Commission to report on opioid payment, adverse incentives, and data (H.R. 5723), H4270 [21MY], H5264, H5265 [19JN]

——— suspend payments by prescription drug plans and Medicare Advantage prescription drug plans pending investigation of credible allegations of fraud by pharmacies (H.R. 5676), H5261–H5264 [19JN], E904 [22JN]

Medicare Payment Advisory Commission: report on opioid payment, adverse incentives, and tracking and monitoring data, H9553 [16NO]

Meningitis B Awareness Day: observance (H. Res. 842), H3458 [24AP]

Mexico: tighten border security to prevent illicit drug flow into U.S., H3435 [18AP]

National Alcohol and Drug Addiction Recovery Month: observance, H8110 [12SE], H9393 [28SE]

National Association of Chain Drug Stores: tribute to annual RxIMPACT Day on Capitol Hill, E251 [5MR]

National Guard: Counterdrug Program funding, H5806, H5807 [27JN]

National Prescription Drug Take Back Day: observance, H3765 [7MY]

National Prescription Drug Take-Back Day: observance, H3689, H3690, H3691 [26AP]

Nobel Prize: recognition of Jim Allison for medicine, E1480 [30OC]

Obama, Barack: allegations of interference in DEA investigation into drug trafficking and money laundering by Hezbollah (terrorist organization) in order to secure agreement relative to Iran’s nuclear program, H68, H69 [9JA]

——— evaluation of administration relative to drug trafficking policies, H6107 [11JY]

Office of National Drug Control Policy: High Intensity Drug Trafficking Area program funding, H6534 [18JY]

——— reauthorize, redesignate as Office of National Drug Control, and enhance authorities to improve Federal drug control efforts (H.R. 5925), H5304–H5325 [20JN]

Office of the Director of National Intelligence: determine if Iran has used funds from sanctions relief or certain payments to sponsor terrorist organizations, for illicit narcotics activities, or military operations in Syria (H.R. 6774), H8905 [26SE]

Packaging: require improved packaging and disposal methods with respect to certain drugs (H.R. 5687), H5234–H5237 [19JN], E904 [22JN]

Palm Beach County, FL: tribute to fight against opioid drug abuse epidemic, E144 [6FE]

Pharmaceuticals: impact of pharmaceutical industry lobbyists and political contributions on prescription drug prices, H4592 [23MY]

——— implement strategy to reduce prescription drug prices, H3867, H3868 [9MY], H3889 [10MY]

——— prescription drug prices, E1325 [27SE]

——— reform the pharmaceutical industry, H3988 [16MY]

——— support antibiotic stewardship programs to ensure proper prescription and administration of antibiotics, E1533 [16NO]

Postal service: prevent entrance of illicit drugs in the U.S. by international airmail, H3435 [18AP]

Postal Service: require foreign shipments to provide electronic advance customs data to U.S. Customs and Border Protection on packages entering the U.S. to help stop trafficking of illicit synthetic drugs, H9248 [28SE]

——— require foreign shipments to provide electronic advance customs data to U.S. Customs and Border Protection on packages entering the U.S. to help stop trafficking of illicit synthetic drugs (H.R. 1057), H764 [5FE]

Prematurity Research Expansion and Education for Mothers Who Deliver Infants Early (PREEMIE) Act: revise and extend (S. 3029), H9578 [27NO], H10054–H10057 [11DE]

Public Health Service: report to Congress on effects on public health of increased rate of use of synthetic drugs (H.R. 449), H5029–H5031 [12JN], E977 [6JY]

Republican Party: national agenda, H6637–H6639 [23JY], H7145 [24JY]

Rohrabacher, Representative: appreciation of opportunity to serve, H9685–H9688 [28NO]

Russia: condemn destabilizing activities and call on Fédération Internationale de Football Association (FIFA) to explain why it continues to plan to hold the World Cup in Russia based on such activities (H. Res. 926), E785 [6JN]

Savannah, GA: tribute to Savannah Police Dept., Cann Park anti-crime operation, H3959 [15MY]

Save a Life Foundation: tribute, H5368 [21JN]

Sports: establish criminal penalties and civil remedies for doping fraud violations at major international competitions (H.R. 6067), H5186–H5188 [14JN], E829 [12JN]

——— use of state-run doping programs by certain foreign countries in international competitions, E1078 [26JY]

States: protect States and individuals in States that have laws which permit the use of marijuana (H.R. 4779), H421 [17JA]

Taxation: allow deductions and credits relating to expenditures in connection with marijuana sales conducted in compliance with State law (H.R. 1810), H472, H473 [17JA], H3503 [24AP]

——— establish an excise tax on production and importation of opioid pain relievers and use such funds to provide and expand access to substance abuse treatment (H.R. 3254), H5140 [13JN]

——— include certain over-the-counter medical products as qualified medical expenses (H.R. 6199), H6572 [19JY], H7095 [24JY], H7651–H7658 [25JY]

——— include certain over-the-counter medical products as qualified medical expenses (H.R. 6199), consideration (H. Res. 1012), H7100–H7106 [24JY]

U.S. Customs and Border Protection: prohibit imposition of civil penalties against Postal Service for acceptance of opioid shipments lacking advance electronic data, H5170 [14JN]

——— provide for processing of certain international mail shipments and advance electronic information on international mail shipments to target opioid shipments, H5515 [22JN]

——— provide for processing of certain international mail shipments and advance electronic information on international mail shipments to target opioid shipments (H.R. 5788), H5001 [8JN], H5163–H5172 [14JN], E901 [22JN]

——— provide for processing of certain international mail shipments and advance electronic information on international mail shipments to target opioid shipments (H.R. 5788), consideration (H. Res. 934), H5107–H5115 [13JN], E841 [14JN]

U.S. Sentencing Commission: restore jurisdication over Federal sentencing guidelines relative to synthetic drug offenses, H5216, H5217 [15JN]

West Virginia: 2d Congressional District internship program for individuals in long-term substance abuse recovery program to meet requirements of obtaining job readiness skills, H5186 [14JN]

World Antibiotic Awareness Week: observance, E1533 [16NO]

World Pharmacists Day: observance, H9139 [27SE]

Remarks in Senate

Advertising: require drug manufacturers to disclose prices of prescription drugs in any direct-to-consumer advertising and marketing to practitioners of a drug, S5406–S5409 [26JY], S5736 [21AU], S5809–S5811 [22AU], S5882–S5884 [23AU], S7221 [29NO]

Azar, Alex M., II: suitability to be Sec. of HHS relative to history of raising prescription drug prices while serving as drug company executive, S458, S461 [23JA], S483–S485, S492 [24JA]

Baltimore, MD: tribute to roundtable discussion with local leadership relative to opioid crisis, S6166 [17SE]

Budget: provide parity for defense and nondefense spending, S33–S35 [4JA]

CDC: reauthorize and expand a program of surveillance and education regarding infections associated with injection drug use, S6162 [17SE], S6463 [3OC]

Central America: encourage partnerships with Mexico and Central American governments to improve their economies and combat cartels, gangs, and traffickers, S7105–S7107 [27NO], S7199–S7201 [29NO], S7374 [10DE]

China: agreement to designate fentanyl as a controlled substance and make export of such drugs subject to maximum penalty under Chinese law, S7341–S7343 [6DE]

Columbus, OH: tribute to Maryhaven Addiction Stabilization Center, S6168 [17SE]

Committee on Health, Education, Labor, and Pensions (Senate): call for investigation of drug companies’ knowledge about addictive qualities of drugs they manufacture, S629 [6FE]

Committee on Homeland Security and Governmental Affairs (Senate): authorize release of Permanent Subcommittee on Investigations records on investigation into purchase and shipment of illicit opioids (S. Res. 379), S475 [23JA]

Committee on the Judiciary (Senate): accomplishments, S7976, S7982–S7984 [20DE]

Comprehensive Addiction and Recovery Act: reauthorize and expand, S6050 [6SE], S6126 [12SE], S6170 [17SE]

——— reauthorize and expand (S. 2456), S1245–S1247 [27FE], S2471 [26AP], S2573 [9MY], S3597 [11JN], S7176 [28NO]

Congress: accomplishments of the 115th Congress, S2889 [24MY], S2973 [5JN], S6941, S6954–S6956 [14NO], S7020, S7022 [15NO], S7073–S7076 [26NO]

Correctional institutions: reform prison system, S571 [30JA]

Courts: allow judges greater discretion in sentencing decisions in Federal cases involving mandatory minimum sentences, S7748, S7749 [18DE]

Crime: establish criminal penalties for unlawful payments for referrals to recovery homes and clinical treatment facilities, S6473 [3OC]

——— reduce recidivism and increase public safety by promoting successful reentry into society of released prisoners and recovery and prevention of drug and alcohol abuse (S. 1994), S2405 [25AP]

——— reform and establish mandatory minimum sentences for certain offenses to provide more flexibility, strengthen penalties for violent crimes, review criminal justice system, and reduce recidivism among Federal inmates (S. 1917), S2676 [15MY]

DEA: address importation of illegal drugs, S4388 [26JN]

——— allow home hospice providers to dispose of leftover prescription medications on behalf of their patients and establish written policies and documentation on such disposals, S6472 [3OC]

——— allow home hospice providers to dispose of leftover prescription medications on behalf of their patients and establish written policies and documentation on such disposals (S. 2659), S2105 [12AP]

——— commemorate anniversary, honor employees killed or injured in service, and thank all past and present employees (S. Res. 578), S5312 [24JY]

——— enhance opioid quota-setting authority by improving transparency and allowing adjustment of opioid production quotas to prevent diversion and abuse, S6174 [17SE]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders, S6471 [3OC]

——— report certain information on distribution of opioids to assist in identifying suspicious orders and hold manufacturers and distributors accountable who fail to report and stop suspicious orders (S. 2838), S2680 [15MY], S3596 [11JN]

——— suspend a controlled substances registration if there is a likelihood of a threat of diversion of a controlled substance (S. 2561), S1766 [15MR]

Dept. of Agriculture: establish a Rural Health Liaison (S. 2894), S2813 [22MY]

——— provide for State and tribal regulation of hemp production, S3863 [13JN], S3929 [14JN], S4459 [27JN], S7390 [11DE]

——— provide for State and tribal regulation of hemp production (S. 2667), S2085, S2086, S2128 [12AP], S2132 [16AP], S3016 [6JN]

Dept. of HHS: allow personal importation of safe and affordable drugs from approved pharmacies in Canada (S. 92), S7221 [29NO]

——— authorize a loan repayment program for substance use disorder treatment employees, S6471 [3OC]

——— authorize Substance Abuse and Mental Health Services Administration development of best practices for recovery residences that promote sustained recovery from substance use disorders (S. 2678), S2142 [16AP]

——— conduct a demonstration program to test alternative pain management protocols to limit use of opioids in emergency departments (S. 2516), S2067 [11AP]

——— conduct a study on the changes in prices of prescription drugs, S5879 [23AU]

——— designate certain substance use disorder treatment facilities as eligible for National Health Service Corps service (S. 1453), S93 [9JA]

——— develop national milestones to measure success in curtailing the opioid epidemic, S6162 [17SE], S6463 [3OC]

——— ensure doctors have access to patients’ treatment history to prevent addiction relapses or harmful drug interactions and protect confidentiality of substance use disorder patient records, S6472 [3OC]

——— establish a grant program to create comprehensive opioid recovery centers, S6164 [17SE], S6471 [3OC]

——— establish a pilot program to help individuals in recovery from a substance use disorder transition from treatment to independent living and the workforce, S6116 [12SE], S6198 [18SE], S6456 [3OC]

——— establish a pilot program to help individuals in recovery from a substance use disorder transition from treatment to independent living and the workforce (S. 2730), S2359 [24AP]

——— establish community action opioid response grant program (S. 2636), S2105 [12AP]

——— establish grant program within the Substance Abuse and Mental Health Services Administration to create peer support recovery networks (S. 2657), S2105 [12AP]

——— improve State response to opioid abuse crisis by prioritizing State Targeted Response to the Opioid Crisis Grants to States with high overdose mortality rates and lack of access to treatment, S6471 [3OC]

——— improve treatment and early interventions for pregnant and postpartum women and infants affected by substance use disorder, S6116 [12SE], S6198 [18SE]

——— improve treatment and early interventions for pregnant and postpartum women and infants affected by substance use disorder (S. 2710), S2289 [19AP], S2359 [24AP]

——— make Indian tribes eligible for State Targeted Response to the Opioid Crisis Grants and expand use to include methamphetamine abuse, S6166 [17SE]

——— provide for sharing of health information concerning an individual’s substance abuse history and treatment by certain entities, S2478 [26AP], S6177 [17SE], S6472 [3OC]

——— provide for sharing of health information concerning an individual’s substance abuse history and treatment by certain entities (S. 581), S1915 [22MR]

——— require drug manufacturers to publicly justify unnecessary price increases (S. 1348), S5880, S5881 [23AU]

——— require Substance Abuse and Mental Health Services Administration to report to Congress on barriers to providing medication-assisted drug treatment to youths, S6161 [17SE]

——— study and submit to Congress a report recommending how to improve use of non-opioid treatments for acute and chronic pain management for individuals under Medicare, S6470 [3OC]

Dept. of Homeland Security: improve ability of U.S. Customs and Border Protection to interdict fentanyl, other synthetic opioids, narcotics, and psychoactive substances illegally imported into the U.S., S6436 [2OC]

——— improve ability of U.S. Customs and Border Protection to interdict fentanyl, other synthetic opioids, narcotics, and psychoactive substances illegally imported into the U.S. (H.R. 2142), S148 [11JA]

——— improve ability of U.S. Customs and Border Protection to interdict fentanyl, other synthetic opioids, narcotics, and psychoactive substances illegally imported into the U.S. (S. 708), S2753 [17MY]

——— strengthen border security and increase resources for enforcement of immigration laws, S82 [9JA], S257, S258 [17JA], S338 [19JA]

——— strengthen border security and increase resources for enforcement of immigration laws (S. 2192), S53, S56–S59 [8JA]

——— support officers and employees of U.S. Immigration and Customs Enforcement and denounce efforts to abolish agency, S5463 [31JY], S5816 [22AU]

——— support officers and employees of U.S. Immigration and Customs Enforcement and denounce efforts to abolish agency (H. Res. 990), S5082 [19JY]

——— support officers and employees of U.S. Immigration and Customs Enforcement and denounce efforts to abolish agency (S. Res. 572), S5045–S5048, S5063 [18JY], S5082, S5083, S5096 [19JY]

——— support officers and employees of U.S. Immigration and Customs Enforcement and denounce efforts to abolish agency (S. Res. 572), unanimous-consent request, S5045 [18JY]

Dept. of Justice: provide for programs to help reduce the risk that prisoners will recidivate upon release from prison (H.R. 5682), S7505 [12DE]

——— provide for programs to help reduce the risk that prisoners will recidivate upon release from prison (S. 2795), S2535 [8MY], S2580 [9MY]

——— provide grants to State and local law enforcement agencies to purchase chemical screening devices to detect dangerous drugs and train personnel on use of such devices (S. 2763), S2554 [8MY], S2753 [17MY]

——— rescission of policy placing a low priority on Federal enforcement of marijuana laws in States with legalized marijuana, S33, S39–S42 [4JA]

Dept. of Labor: establish Jobs Plus Recovery programs to give individuals impacted by opioid addiction or substance use disorders access to job training and support services (S. 2642), S2042 [10AP]

Dept. of the Treasury: Office of Terrorism and Financial Intelligence funding to investigate illicit trade of synthetic opioids originating from the People’s Republic of China, S5351 [25JY]

Dept. of Transportation: improve controlled substances and alcohol testing, S6210 [18SE]

Depts. of Labor and HHS: establish a pilot program to award competitive grants to counties and tribal entities to administer combined workforce training and drug addiction treatment and recovery programs, S6471 [3OC]

——— establish a pilot program to award competitive grants to counties and tribal entities to administer combined workforce training and drug addiction treatment and recovery programs (S. 2646), S2555 [8MY]

Diseases and disorders: authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur within a matter of months, or with another eligible illness (H.R. 5247), S1981, S1982 [22MR], S1994 [9AP]

——— authorize use of eligible investigational drugs by patients diagnosed with a disease or condition in which death will occur, or with another eligible illness (H.R. 5247), unanimous-consent request, S1981 [22MR]

Donnelly, Senator: appreciation of opportunity to serve, S7406–S7409 [11DE]

Drug abuse: address opioid drug abuse epidemic by securing the southern border, S7393 [11DE], S7554–S7556 [13DE]

——— address prescription opioid and heroin abuse, S2066 [11AP], S2414 [25AP], S2463, S2469–S2472 [26AP], S2909–S2911 [24MY], S2973 [5JN], S3873, S3874 [13JN], S4491, S4492 [27JN], S5049 [18JY], S5101–S5103 [19JY], S5326 [25JY], S5603–S5606 [15AU], S5746–S5748 [21AU], S6209 [18SE], S6796 [11OC], S7175–S7178 [28NO], S7573–S7575 [13DE], S7841 [19DE]

——— extend authority of nurse practitioners to provide medication-assisted treatment for opioid use disorders, S6163 [17SE]

——— making appropriations to address heroin and opioid drug abuse epidemic, S146–S148 [11JA], S280 [18JA], S321 [19JA], S629 [6FE], S812–S815 [8FE], S887 [12FE], S6210 [18SE]

——— prevent substance abuse and reduce demand for illicit narcotics, S6120 [12SE]

——— provide for additional flexibility relative to medication-assisted treatment for opioid use disorders, S6162 [17SE], S6463, S6469 [3OC]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), S4376 [25JN], S4380 [26JN], S6048–S6050 [6SE], S6116–S6121, S6126, S6149 [12SE], S6159–S6170, S6172–S6178 [17SE], S6198, S6210, S6215–S6217, S6218 [18SE], S7177 [28NO]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), House amendment, S6432–S6436 [2OC], S6456, S6459, S6463, S6467, S6468–S6474, S6477–S6484, S6489, S6491 [3OC], S6796–S6798 [11OC]

——— provide for opioid use disorder prevention, recovery, and treatment (H.R. 6), unanimous-consent agreement, S6105 [6SE], S6457 [3OC]

——— strengthen penalties on drug companies that fail to monitor and report suspicious opioid distribution practices and increase transparency of Federal oversight of opioid manufacturing and advertising, S3596 [11JN], S6173 [17SE]

Economy: address low labor force participation rates by increasing efforts to provide skills training, reduce dependency on Federal aid programs, integrate previously incarcerated individuals into workforce, and address opioid crisis, S2571–S2574 [9MY]

FDA: prohibit abusive delay tactics by pharmaceutical companies to block entry of generic drugs and biosimilar biological products from the market (S. 974), S807 [8FE], S5881 [23AU], S7221 [29NO]

——— provide for accelerated approval of non-opioid or non-addictive pain medications and treatments for substance use disorders, S6470 [3OC]

——— reauthorize user fee programs relative to new animal drugs and generic new animal drugs (H.R. 5554), S5472–S5474, S5508 [31JY], S5576 [1AU]

——— require warning labels to be affixed to prescription opioid containers or packaging stating such drugs can cause dependence, addiction, and overdose (S. 3428), S6162 [17SE], S6463 [3OC]

FTC: prohibit marketing of bogus opioid treatment programs or products, S6471 [3OC]

Government regulations: prevent regulatory oversight from disrupting ability of emergency medical personnel to administer certain controlled substances (S. 916), S2882–S2884 [23MY]

Health: emergency medical services resources funding, S4841 [9JY]

——— national policy to provide health care and reform insurance procedures, S7391–S7393 [11DE]

Health care professionals: improve medical student training on addiction treatment and facilitate certain registration waivers for physicians dispensing narcotic drugs for maintenance treatment or detoxification treatment, S6164 [17SE]

Immigration: secure the border between the U.S. and Mexico, S7105–S7107 [27NO], S7199–S7201, S7205–S7207 [29NO], S7373–S7375, S7377–S7379 [10DE], S7393 [11DE], S7823, S7827 [19DE], S8022, S8025 [22DE]

Insurance: ensure that health insurance issuers and group health plans do not prohibit pharmacy providers from providing certain information to enrollees (S. 2554), S2664–S2667 [15MY], S6164, S6170–S6173, S6175, S6176, S6178 [17SE], S7221 [29NO]

——— ensure that health insurance issuers and group health plans do not prohibit pharmacy providers from providing certain information to enrollees (S. 2554), unanimous-consent agreement, S6105 [6SE]

——— ensure that self-insured group health insurance plans that are exempt from State regulations do not prohibit pharmacy providers from providing certain information to enrollees, S6178 [17SE]

——— limit application of provision to prohibit pharmacy providers from providing certain information to enrollees to self-insured group health plans, S6171, S6172 [17SE]

Kaléo, Inc.: Senate investigation of pricing of naloxone auto-injector to reverse effects of overdoses, S7574 [13DE]

Law enforcement: address trafficking of illicit fentanyl, S3945–S3947 [14JN], S6049 [6SE]

——— improve prosecution of the sale and distribution of synthetic drugs known as analogues, S6473 [3OC]

——— strengthen mental health system, improve public safety, and reauthorize and improve the National Instant Criminal Background Check System, S2785 [21MY]

Marijuana: allow States, territories, and Indian tribes to control regulation, remove industrial hemp from list of controlled substances, and maintain application of certain criminal offenses, S7753 [18DE]

Medicaid: allow States to provide medical assistance at a residential pediatric recovery center to infants under 1 year of age with neonatal abstinence syndrome and their families, S6050 [6SE], S6127 [12SE], S6170 [17SE], S6436 [2OC], S6472 [3OC], S6797 [11OC], S7177 [28NO]

——— allow States to provide services for certain individuals with opioid use disorders in mental institutions, S6174 [17SE], S6480–S6482 [3OC]

——— prevent misclassification of drugs for purposes of the drug rebate program (S. 3702), S7339 [6DE]

——— provide for a demonstration project to increase substance use provider treatment capacity, S6169 [17SE]

Medicare: establish part E public health plans available to everyone (S. 2708), S2265 [18AP]

——— expand use of telehealth services for treatment of opioid use disorder and other substance use disorders, S6210 [18SE]

——— prohibit health plans and pharmacy benefit managers from restricting pharmacies from informing individuals regarding prices for certain drugs and biologicals (S. 2553), S2664–S2667 [15MY], S6033 [4SE], S6173 [17SE]

——— prohibit health plans and pharmacy benefit managers from restricting pharmacies from informing individuals regarding prices for certain drugs and biologicals (S. 2553), correction in enrollment (S. Con. Res. 49), S6375 [28SE]

——— require the Dept. of HHS to negotiate lower covered part D prescription drug prices for beneficiaries (S. 41), S5880 [23AU]

Mental Health Parity and Addiction Equity Act: anniversary (S. Res. 670), S6773 [10OC]

National Alcohol and Drug Addiction Recovery Month: observance (S. Res. 669), S6546 [4OC]

National Criminal Justice Commission: establish (S. 573), S8037 [22DE]

National Drug Court Month: observance, S2675 [15MY]

National Prescription Drug Take-Back Day: observance, S2464 [26AP]

Obama, Barack: allegations of interference in DEA investigation into drug trafficking and money laundering by Hezbollah (terrorist organization) in order to secure agreement relative to Iran’s nuclear program, S16 [3JA]

Office of National Drug Control Policy: funding, S333 [19JA]

Pharmaceuticals: implement strategy to reduce prescription drug prices, S2601 [10MY], S2691 [16MY]

——— improve access to affordable prescription drugs, S7220 [29NO]

——— prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market (S. 124), S7220 [29NO], S7889 [19DE]

Positive Street Art (organization): tribute, S5912 [23AU]

Postal Service: require foreign shipments to provide electronic advance customs data to U.S. Customs and Border Protection on packages entering the U.S. to help stop trafficking of illicit synthetic drugs, S6049 [6SE], S6166 [17SE], S6215–S6217 [18SE], S6432, S6436 [2OC], S6471, S6473 [3OC], S6797 [11OC]

——— require foreign shipments to provide electronic advance customs data to U.S. Customs and Border Protection on packages entering the U.S. to help stop trafficking of illicit synthetic drugs (S. 372), S568 [30JA], S813 [8FE], S2470 [26AP], S2573 [9MY], S2637 [14MY], S2765–S2768 [17MY], S2909–S2911 [24MY], S3743 [12JN], S4492 [27JN], S5102 [19JY], S5605 [15AU], S5747 [21AU]

Prematurity Research Expansion and Education for Mothers Who Deliver Infants Early (PREEMIE) Act: revise and extend (S. 3029), S6153 [12SE]

Senate: legislative priorities, S3 [3JA], S82 [9JA], S114–S116 [10JA], S276 [18JA], S446 [23JA], S512–S514 [25JA], S544 [29JA], S1773 [19MR]

Sessions, Attorney General: assessment of tenure, S668–S670 [7FE]

Taxation: establish an excise tax on production and importation of opioid pain relievers and use such funds to provide and expand access to substance abuse treatment (S. 523), S6473 [3OC]

Trump, President: evaluation of administration, S2658 [15MY]

U.S. Customs and Border Protection: provide for processing of certain international mail shipments and advance electronic information on international mail shipments to target opioid shipments, S6127 [12SE], S6169 [17SE], S6469, S6489 [3OC]

——— provide for processing of certain international mail shipments and advance electronic information on international mail shipments to target opioid shipments (H.R. 5788), S3945–S3947 [14JN]

‘‘War on Drugs’’: impact, S39–S42 [4JA]

Reports

Opioid Crisis in Illinois—Data and the State’s Response: Illinois Dept. of Human Services, H5169 [14JN]

Reports filed

Abuse Deterrent Access Act: Committee on Energy and Commerce (House) (H.R. 5582) (H. Rept. 115–721), H5020 [8JN]

Access to Increased Drug Disposal Act: Committee on the Judiciary (Senate) (S. 2645), S4035 [19JN]

Access to Telehealth Services for Opioid Use Disorders Act: Committee on Energy and Commerce (House) (H.R. 5603) (H. Rept. 115–745), H5092 [12JN]

Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act: Committee on Energy and Commerce (House) (H.R. 5605) (H. Rept. 115–744), H5092 [12JN]

Border Security for America Act: Committee on Homeland Security (House) (H.R. 3548) (H. Rept. 115–505), H131 [10JA]

Border Tunnel Task Force Act: Committee on Homeland Security (House) (H.R. 6740) (H. Rept. 115–962), H8882 [25SE]

Combating Opioid Abuse for Care in Hospitals (COACH) Act: Committee on Ways and Means (House) (H.R. 5774) (H. Rept. 115–762), H5283 [19JN]

Commit to Opioid Medical Prescriber Accountability and Safety for Seniors (COMPASS) Act: Committee on Energy and Commerce (House) (H.R. 5716) (H. Rept. 115–740), H5092 [12JN]

Consideration of H.R. 6, Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: Committee on Rules (House) (H. Res. 949) (H. Rept. 115–766), H5283 [19JN]

Consideration of H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act: Committee on Rules (House) (H. Res. 934) (H. Rept. 115–751), H5092 [12JN]

Consideration of H.R. 4456, Alleviating Stress Test Burdens To Help Investors Act and H.R. 5247, Right To Try Act: Committee on Rules (House) (H. Res. 787) (H. Rept. 115–613), H1697 [19MR]

Consideration of H.R. 5735, Transitional Housing for Recovery in Viable Environments Demonstration Program (THRIVE) Act: Committee on Rules (House) (H. Res. 934) (H. Rept. 115–751), H5092 [12JN]

Consideration of H.R. 5788, Securing the International Mail Against Opioids Act: Committee on Rules (House) (H. Res. 934) (H. Rept. 115–751), H5092 [12JN]

Consideration of H.R. 5797, Individuals in Medicaid Deserve Care That Is Appropriate and Responsible in Its Execution (IMD CARE) Act: Committee on Rules (House) (H. Res. 949) (H. Rept. 115–766), H5283 [19JN]

Consideration of H.R. 6082, Overdose Prevention and Patient Safety Act: Committee on Rules (House) (H. Res. 949) (H. Rept. 115–766), H5283 [19JN]

Consideration of H.R. 6136, Border Security and Immigration Reform Act: Committee on Rules (House) (H. Res. 953) (H. Rept. 115–771), H5361 [20JN]

Consideration of H.R. 6199, Restoring Access to Medication and Modernizing Health Savings Accounts Act: Committee on Rules (House) (H. Res. 1012) (H. Rept. 115–861), H6648 [23JY]

Consideration of S. 204, Right To Try Act: Committee on Rules (House) (H. Res. 905) (H. Rept. 115–698), H4283 [21MY]

Coordinated Response Through Interagency Strategy and Information Sharing (CRISIS) Act: Committee on Oversight and Government Reform (House) (H.R. 5925) (H. Rept. 115–767), H5361 [20JN]

Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act: Committee on the Judicary (Senate) (S. 974), S4343 [21JN]

Every Prescription Conveyed Securely Act: Committee on Energy and Commerce (House) (H.R. 3528) (H. Rept. 115–748), H5092 [12JN]

Expanding Oversight of Opioid Prescribing and Payment Act: Committee on Ways and Means (House) (H.R. 5723) (H. Rept. 115–760), H5283 [19JN]

FDA User Fee Programs Relative to New Animal Drugs and Generic New Animal Drugs Reauthorization: Committee on Health, Education, Labor and Pensions (Senate) (S. 2434), S1452 [7MR]

Fight Illicit Networks and Detect (FIND) Trafficking Act: Committee on Financial Services (House) (H.R. 6069) (H. Rept. 115–781), H5647 [25JN]

Fighting Opioid Abuse in Transportation Act: Committee on Commerce, Science, and Transportation (Senate) (S. 2848) (S. Rept. 115–286), S4512 [27JN]

Formerly Incarcerated Reenter Society Transformed Safely Transitioning Every Person (FIRST STEP) Act: Committee on the Judiciary (House) (H.R. 5682) (H. Rept. 115–699), H4582 [22MY]

Helping To End Addiction and Lessen Substance Use Disorders (HEAL) Act: Committee on Finance (Senate) (S. 3120) (S. Rept. 115–284), S4368 [25JN]

Homeland Security for Children Act: Committee on Homeland Security and Governmental Affairs (Senate) (S. 1847) (S. Rept. 115–201), S580 [30JA]

Individuals in Medicaid Deserve Care That Is Appropriate and Responsible in Its Execution (IMD CARE) Act: Committee on Energy and Commerce (House) (H.R. 5797) (H. Rept. 115–723), H5091 [12JN]

Joint Task Force To Combat Opioid Trafficking Act: Committee on Homeland Security (House) (H.R. 5762) (H. Rept. 115–755), H5199 [14JN]

Medicaid Coverage Protections for Pregnant and Post-Partum Women While Receiving Inpatient Treatment for a Substance Use Disorder: Committee on Energy and Commerce (House) (H.R. 5789) (H. Rept. 115–730), H5091 [12JN]

Medicaid Drug Review, Utilization, Good Governance (Medicaid DRUG) Improvement Act: Committee on Energy and Commerce (House) (H.R. 5799) (H. Rept. 115–728), H5091 [12JN]

Medicaid Health Homes for Opioid-Use-Disorder Medicaid Enrollees Encouraged (Medicaid Health HOME) Act: Committee on Energy and Commerce (House) (H.R. 5810) (H. Rept. 115–727), H5091 [12JN]

Medicaid Pharmaceutical Home Act: Committee on Energy and Commerce (House) (H.R. 5808) (H. Rept. 115–726), H5091 [12JN]

Medicaid Providers Are Required To Note Experiences in Record Systems To Help In-Need Patients (Medicaid PARTNERSHIP) Act: Committee on Energy and Commerce (House) (H.R. 5801) (H. Rept. 115–725), H5091 [12JN]

Medicare and Opioid Safe Treatment (MOST) Act: Committee on Ways and Means (House) (H.R. 5776) (H. Rept. 115–764), H5283 [19JN]

Medicare Clear Health Options in Care for Enrollees (Medicare CHOICE) Act: Committee on Energy and Commerce (House) (H.R. 5686) (H. Rept. 115–741), H5092 [12JN]

Medicare Opioid Safety Education Act: Committee on Energy and Commerce (House) (H.R. 5685) (H. Rept. 115–715), H5020 [8JN]

Nomination of James W. Carroll, Jr., To Be Office of National Drug Control Policy Director: Committee on the Judiciary (Senate), S6189 [17SE]

Opioid Addiction Action Plan Act: Committee on Energy and Commerce (House) (H.R. 5590) (H. Rept. 115–746), H5092 [12JN]

Opioid Addiction Recovery Fraud Prevention Act: Committee on Commerce, Science, and Transportation (Senate) (S. 2842) (S. Rept. 115–285), S4512 [27JN]

Opioid Crisis Response Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 2680), S2517 [7MY]

Opioid Quota Reform Act: Committee on the Judiciary (Senate) (S. 2535), S4035 [19JN]

Opioid Screening and Chronic Pain Management Alternatives for Seniors Act: Committee on Energy and Commerce (House) (H.R. 5798) (H. Rept. 115–739), H5092 [12JN]

Opportunities To Provide for Illicit Opioid Interdiction and Detection (OPIOID) Act: Committee on Homeland Security and Governmental Affairs (Senate) (S. 3047) (S. Rept. 115–353), S6924 [13NO]

Overdose Prevention and Patient Safety Act: Committee on Energy and Commerce (House) (H.R. 5795) (H. Rept. 115–724), H5091 [12JN]

Over-the-Counter Drug Safety, Innovation, and Reform Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 2315), S2642 [14MY]

Over-the-Counter Monograph Safety, Innovation, and Reform Act: Committee on Energy and Commerce (House) (H.R. 5333) (H. Rept. 115–827), H6262 [16JY]

Patient Right To Know Drug Prices Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 2554), S5516 [31JY]

Postoperative Opioid Prevention Act: Committee on Energy and Commerce (House) (H.R. 5809) (H. Rept. 115–753), H5151 [13JN]

Prematurity Research Expansion and Education for Mothers Who Deliver Infants Early (PREEMIE) Act Revision and Extension: Committee on Health, Education, Labor, and Pensions (Senate) (S. 3029), S4843 [9JY]

Preventing Addiction for Susceptible Seniors (PASS) Act: Committee on Ways and Means (House) (H.R. 5773) (H. Rept. 115–761), H5283 [19JN]

Preventing Drug Diversion Act: Committee on the Judiciary (Senate) (S. 2837), S4035 [19JN]

Protecting Seniors From Opioid Abuse Act: Committee on Energy and Commerce (House) (H.R. 5684) (H. Rept. 115–742), H5092 [12JN]

Providing Reliable Options for Patients and Educational Resources (PROPER) Act: Committee on Ways and Means (House) (H.R. 5775) (H. Rept. 115–763), H5283 [19JN]

Require Medicare Prescription Drug Plan Sponsors To Establish Drug Management Programs for At-Risk Beneficiaries: Committee on Energy and Commerce (House) (H.R. 5675) (H. Rept. 115–743), H5092 [12JN]

Responsible Education Achieves Care and Healthy Outcomes for Users’ Treatment (REACH OUT) Act: Committee on Energy and Commerce (House) (H.R. 5796) (H. Rept. 115–729), H5091 [12JN]

Restoring Access to Medication and Modernizing Health Savings Accounts Act: Committee on Ways and Means (House) (H.R. 6199) (H. Rept. 115–850), H6587 [19JY]

Rural Development of Opioid Capacity Services (Rural DOCS) Act: Committee on Energy and Commerce (House) (H.R. 5477) (H. Rept. 115–731), H5091 [12JN]

Securing the International Mail Against Opioids Act: Committee on Ways and Means (House) (H.R. 5788) (H. Rept. 115–722), H5020 [8JN]

Standardizing Electronic Prior Authorization for Safe Prescribing Act: Committee on Energy and Commerce (House) (H.R. 4841) (H. Rept. 115–747), H5092 [12JN]

Stop Excessive Narcotics in Our Retirement (SENIOR) Communities Protection Act: Committee on Ways and Means (House) (H.R. 5676) (H. Rept. 115–759), H5283 [19JN]

Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act: Committee on the Judiciary (House) (H.R. 2851) (H. Rept. 115–713), H5020 [8JN]

Substance Abuse Prevention Act: Committee on the Judiciary (Senate) (S. 2789), S4035 [19JN]

Synthetic Abuse and Labeling of Toxic Substances (SALTS) Act: Committee on the Judiciary (Senate) (S. 207), S4035 [19JN]

Transitional Housing for Recovery in Viable Environments Demonstration Program (THRIVE) Act: Committee on Financial Services (House) (H.R. 5735) (H. Rept. 115–719), H5020 [8JN]

Treating Barriers to Prosperity Act: Committee on Transportation and Infrastructure (House) (H.R. 5294) (H. Rept. 115–749), H5092 [12JN]

Using Data To Prevent Opioid Diversion Act: Committee on the Judiciary (Senate) (S. 2838), S4035 [19JN]

Veterans Affairs Medical-Surgical Purchasing Stabilization Act: Committee on Veterans’ Affairs (House) (H.R. 5418) (H. Rept. 115–693), H4283 [21MY]

Veterans Opioid Abuse Prevention Act: Committee on Veterans’ Affairs (House) (H.R. 3832) (H. Rept. 115–684), H4241 [18MY]

Statements

Opioid Epidemic: Jean and Dave Duffy, H5171 [14JN]

Right To Try Act: Senator Johnson, H4360 [22MY]

Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act: American Society of Addiction Medicine, H9252 [28SE]

——— National Association for Behavorial Healthcare, H9251 [28SE]

——— Simona Combi, First Focus Campaign for Children (organization), H9250 [28SE]

Summaries

Animal Drug User Fee Amendments Goals and Procedures: FDA, S5509–S5511 [31JY]

Animal Generic Drug User Fee Amendments Goals and Procedures: FDA, S5576 [1AU]

Texts of

H. Res. 787, consideration of H.R. 5247, Right To Try Act, H1704 [20MR]

H. Res. 905, consideration of S. 204, Right To Try Act, H4292 [22MY]

H. Res. 934, consideration of H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act, H5107 [13JN]

H. Res. 934, consideration of H.R. 5735, Transitional Housing for Recovery in Viable Environments Demonstration Program (THRIVE) Act, H5107 [13JN]

H. Res. 934, consideration of H.R. 5788, Securing the International Mail Against Opioids Act, H5107 [13JN]

H. Res. 949, consideration of H.R. 6, Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, H5294 [20JN]

H. Res. 949, consideration of H.R. 5797, Individuals in Medicaid Deserve Care That Is Appropriate and Responsible in Its Execution (IMD CARE) Act, H5294 [20JN]

H. Res. 949, consideration of H.R. 6082, Overdose Prevention and Patient Safety Act, H5294 [20JN]

H. Res. 953, consideration of H.R. 6136, Border Security and Immigration Reform Act, H5438 [21JN]

H. Res. 990, support officers and employees of U.S. Immigration and Customs Enforcement and denounce efforts to abolish agency, H6486 [18JY]

H. Res. 1012, consideration of H.R. 6199, Restoring Access to Medication and Modernizing Health Savings Accounts Act, H7100 [24JY]

H. Res. 1099, concur in Senate amendment to H.R. 6, Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, H9174–H9242 [28SE]

H.R. 6, Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act, H5522–H5560 [22JN]

H.R. 449, Synthetic Drug Awareness Act, H5029 [12JN]

H.R. 2851, Stop the Importation and Trafficking of Synthetic Analogues (SITSA) Act, H5212–H5215 [15JN]

H.R. 3832, Veterans Opioid Abuse Prevention Act, H4250 [21MY]

H.R. 4275, Empowering Pharmacists in the Fight Against Opioid Abuse Act, H5066 [12JN]

H.R. 4284, Indexing Narcotics, Fentanyl, and Opioids (INFO) Act, H5034 [12JN]

H.R. 4684, Ensuring Access to Quality Sober Living Act, H5036 [12JN]

H.R. 5009, Dept. of HHS sharing of health information concerning an individual’s substance abuse history and treatment by certain entities, H5042 [12JN]

H.R. 5041, Safe Disposal of Unused Medication Act, H5043 [12JN]

H.R. 5102, Substance Use Disorder Workforce Loan Repayment Act, H5045 [12JN]

H.R. 5176, Preventing Overdoses While in Emergency Rooms Act, H5047 [12JN]

H.R. 5197, Alternatives to Opioids in the Emergency Department (ALTO) Act, H5067 [12JN]

H.R. 5228, Stop Counterfeit Drugs by Regulating and Enhancing Enforcement Now (SCREEN) Act, H5049–H5051 [12JN]

H.R. 5247, Right To Try Act, H1521 [13MR], H1738 [21MR]

H.R. 5261, Treatment, Education, and Community Help (TEACH) To Combat Addiction Act, H5052 [12JN]

H.R. 5272, ensure that Dept. of HHS federally-funded programs and activities to prevent or treat mental health or substance use disorders are evidence-based, H5053 [12JN]

H.R. 5294, Treating Barriers to Prosperity Act, H5115 [13JN]

H.R. 5327, Comprehensive Opioid Recovery Centers Act, H5055 [12JN]

H.R. 5333, Over-the-Counter Monograph Safety, Innovation, and Reform Act, H6227–H6235 [16JY]

H.R. 5353, Eliminating Opioid Related Infectious Diseases Act, H5059 [12JN]

H.R. 5418, Veterans Affairs Medical-Surgical Purchasing Stabilization Act, H4257 [21MY]

H.R. 5473, Better Pain Management Through Better Data Act, H5031 [12JN]

H.R. 5483, Special Registration for Telemedicine Clarification Act, H5060 [12JN]

H.R. 5554, FDA user fee programs relative to new animal drugs and generic new animal drugs reauthorization, H6237–H6241 [16JY]

H.R. 5582, Abuse Deterrent Access Act, H5061 [12JN]

H.R. 5587, Peer Support Communities of Recovery Act, H5069 [12JN]

H.R. 5590, Opioid Addiction Action Plan Act, H5247 [19JN]

H.R. 5605, Advancing High Quality Treatment for Opioid Use Disorders in Medicare Act, H5239–H5241 [19JN]

H.R. 5676, Stop Excessive Narcotics in Our Retirement (SENIOR) Communities Protection Act, H5261 [19JN]

H.R. 5682, Formerly Incarcerated Reenter Society Transformed Safely Transitioning Every Person (FIRST STEP) Act, H4302–H4310 [22MY]

H.R. 5685, Medicare Opioid Safety Education Act, H5064 [12JN]

H.R. 5687, Securing Opioids and Unused Narcotics With Deliberate (SOUND) Disposal and Packaging Act, H5234 [19JN]

H.R. 5723, Expanding Oversight of Opioid Prescribing and Payment Act, H5264 [19JN]

H.R. 5735, Transitional Housing for Recovery in Viable Environments Demonstration Program (THRIVE) Act, H5179 [14JN]

H.R. 5752, Stop Illicit Drug Importation Act, H5117 [13JN]

H.R. 5762, Joint Task Force To Combat Opioid Trafficking Act, H5267 [19JN]

H.R. 5773, Preventing Addiction for Susceptible Seniors (PASS) Act, H5258 [19JN]

H.R. 5774, Combating Opioid Abuse for Care in Hospitals (COACH) Act, H5254 [19JN]

H.R. 5775, Providing Reliable Options for Patients and Educational Resources (PROPER) Act, H5256 [19JN]

H.R. 5788, Synthetics Trafficking and Overdose Prevention (STOP) Act, H5164–H5166 [14JN]

H.R. 5796, Responsible Education Achieves Care and Healthy Outcomes for Users’ Treatment (REACH OUT) Act, H5237 [19JN]

H.R. 5797, Individuals in Medicaid Deserve Care That Is Appropriate and Responsible in Its Execution (IMD CARE) Act, H5338 [20JN]

H.R. 5801, Medicaid Providers Are Required To Note Experiences in Record Systems To Help In-Need Patients (Medicaid PARTNERSHIP) Act, H5245–H5247 [19JN]

H.R. 5811, amend FDA policies relative to postapproval study requirements for certain controlled substances, H5243 [19JN]

H.R. 5812, Creating Opportunities That Necessitate New and Enhanced Connections That Improve Opioid Navigation Strategies (CONNECTIONS) Act, H5071–H5073 [12JN]

H.R. 5889, Recognizing Early Childhood Trauma Related to Substance Abuse Act, H5124 [13JN]

H.R. 5890, Assisting States’ Implementation of Plans of Safe Care Act, H5125 [13JN]

H.R. 5891, Improving the Federal Response to Families Impacted by Substance Use Disorder Act, H5127 [13JN]

H.R. 5892, Dept. of Labor Advisory Committee on Opioids and the Workplace establishment, H5129 [13JN]

H.R. 5925, Coordinated Response Through Interagency Strategy and Information Sharing (CRISIS) Act, H5304–H5321 [20JN]

H.R. 6029, Reauthorizing and Extending Grants for Recovery From Opioid Use Programs (REGROUP) Act, H5121 [13JN]

H.R. 6069, Fight Illicit Networks and Detect (FIND) Trafficking Act, H5589 [25JN]

H.R. 6082, Overdose Prevention and Patient Safety Act, H5325 [20JN]

H.R. 6110, Pain Management, Treatment, and Recovery Act, H5250–H5252 [19JN]

H.R. 6136, Border Security and Immigration Reform Act, H5450–H5481 [21JN]

H.R. 6199, Restoring Access to Medication and Modernizing Health Savings Accounts Act, H7651–H7653 [25JY]

H.R. 6740, Border Tunnel Task Force Act, H8748 [25SE]

H.R. 7328, Pandemic and All-Hazards Preparedness and Advancing Innovation Act, H10366–H10391 [20DE]

S. 204, Right To Try Act, H4355 [22MY]

S. 573, National Criminal Justice Commission Act, S8037–S8039 [22DE]

S. 916, Protecting Patient Access to Emergency Medications Act, S2882–S2884 [23MY]

S. 2535, Opioid Quota Reform Act, S1632 [12MR]

S. 2553, Know the Lowest Price Act, S6033 [4SE], H8799 [25SE]

S. 2554, Patient Right To Know Drug Prices Act, H8795 [25SE]

S. 2667, Hemp Farming Act, S2124 [12AP]

S. 2710, Protecting Moms and Infants Act, S2323 [19AP]

S. 2729, Addiction Prevention and Responsible Opioid Practices Act, S2343–S2346 [23AP]

S. 2730, Comprehensive Addiction Recovery Through Effective Employment and Reentry (CAREER) Act, S2346–S2348 [23AP]

S. 2789, Substance Abuse Prevention Act, S2487–S2490 [26AP]

S. 2795, Formerly Incarcerated Reenter Society Transformed Safely Transitioning Every Person (FIRST STEP) Act, S2518–S2527 [7MY]

S. 3029, Prematurity Research Expansion and Education for Mothers Who Deliver Infants Early (PREEMIE) Act revision and extension, S6154 [12SE], H10054 [11DE]

S. 3174, Marijuana Freedom and Opportunity Act, S4740 [28JN]

S. Con. Res. 49, correction in enrollment of S. 2553, Know the Lowest Price Act, S6390 [28SE], H9412 [2OC]

S. Res. 371, recognize importance of bilateral relationship between the U.S. and Mexico in areas of trade, security, law enforcement, energy, economy, and culture and encourage strengthening of NAFTA, S141 [10JA]

S. Res. 379, Committee on Homeland Security and Governmental Affairs (Senate) Permanent Subcommittee on Investigations release of records on investigation into purchase and shipment of illicit opioids, S470 [23JA]

S. Res. 437, support goals of World Tuberculosis Day, S1792 [19MR]

S. Res. 507, recognize importance of goal of National Women’s Health Week to empower young women to make informed choices about sexual activity and take effective steps to protect against HIV, S2681 [15MY]

S. Res. 572, support U.S. Immigration and Customs Enforcement officers and employees of and denounce efforts to abolish agency, S4918 [11JY]

S. Res. 578, commemorate DEA anniversary, honor employees killed or injured in service, and thank all past and present employees, S5070 [18JY]

S. Res. 600, World Hepatitis Day, S5520 [31JY]

S. Res. 611, support officers and employees of U.S. Immigration and Customs Enforcement, condemn harassment and threats against such individuals, and call for resignation of Portland, OR, Mayor, Ted Wheeler, S5763 [21AU]

S. Res. 669, National Alcohol and Drug Addiction Recovery Month, S6545 [4OC]

S. Res. 670, Mental Health Parity and Addiction Equity Act anniversary, S6733 [9OC]

S. Res. 690, affirm importance and commend life-saving accomplishments of Orphan Drug Act, and recognize need and continued support for research in development of therapies, treatments, and cures for rare diseases, S7055 [15NO]